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Background: Biological treatments such as adalimumab (Humira®; AbbVie Ltd, Maidenhead, UK) are
antibodies targeting tumour necrosis factor alpha, released from ruptured intervertebral discs, which might
be useful in sciatica. Recent systematic reviews concluded that they might be effective, but that a definitive
randomised controlled trial was needed. Usual care in the NHS typically includes a physiotherapy intervention.
Objectives: To test whether or not injections of adalimumab plus physiotherapy are more clinically
effective and cost-effective than injections of saline plus physiotherapy for patients with sciatica.
Design: Pragmatic, parallel-group, randomised controlled trial with blinded participants and clinicians, and
an outcome assessment and statistical analysis with concurrent economic evaluation and internal pilot.
Setting: Participants were referred from primary care and musculoskeletal services to outpatient
physiotherapy clinics.
Participants: Adults with persistent symptoms of sciatica of 1–6 months’ duration and with moderate to
high levels of disability. Eligibility was assessed by research physiotherapists according to clinical criteria for
diagnosing sciatica.
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Interventions: After a second eligibility check, trial participants were randomised to receive two doses of
adalimumab (80 mg and then 40 mg 2 weeks later) or saline injections. Both groups were referred for a
course of physiotherapy.
Main outcome measures: Outcomes were measured at the start, and after 6 weeks’ and 6 months’
follow-up. The main outcome measure was the Oswestry Disability Index (ODI). Other outcomes: leg pain
version of the Roland–Morris Disability Questionnaire, Sciatica Bothersomeness Index, EuroQol-5
Dimensions, 5-level version, Hospital Anxiety and Depression Scale, resource use, risk of persistent
disabling pain, pain trajectory based on a single question, Pain Self-Efficacy Questionnaire, Tampa Scale of
Kinesiophobia and adverse effects.
Sample size: To detect an effect size of 0.4 with 90% power, a 5% significance level for a two-tailed
t-test and 80% retention rate, 332 participants would have needed to be recruited.
Analysis plan: The primary effectiveness analysis would have been linear mixed models for repeated
measures to measure the effects of time and group allocation. An internal pilot study would have involved
the first 50 participants recruited across all centres. The primary economic analysis would have been a
cost–utility analysis.
Results: The internal pilot study was discontinued as a result of low recruitment after eight participants
were recruited from two out of six sites. One site withdrew from the study before recruitment started,
one site did not complete contract negotiations and two sites signed contracts shortly before trial closure.
In the two sites that did recruit participants, recruitment was slow. This was partly because of operational
issues, but also because of a low rate of uptake from potential participants.
Limitations: Although large numbers of invitations were sent to potential participants, identified by
retrospective searches of general practitioner (GP) records, there was a low rate of uptake. Two sites
planned to recruit participants during GP consultations but opened too late to recruit any participants.
Conclusion: The main failure was attributable to problems with contracts. Because of this we were not
able to complete the internal pilot or to test all of the different methods for primary care recruitment we
had planned. A trial of biological therapy in patients with sciatica still needs to be done, but would require
a clearer contracting process, qualitative research to ensure that patients would be willing to participate,
and simpler recruitment methods.
Trial registration: Current Controlled Trials ISRCTN14569274.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 60.
See the NIHR Journals Library website for further project information.
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Plain English summary
Sciatica is a severe leg pain usually caused by inflammatory chemicals released from a rupturedintervertebral disc irritating a nerve as it leaves the spine. Biological treatments such as adalimumab
(Humira®, AbbVie Ltd, Maidenhead, UK) block the effects of these chemicals and may be effective for
treating sciatica.
We aimed to test whether or not adalimumab injections plus physiotherapy are more effective, and better
value for money, than saline injections plus physiotherapy for patients with sciatica.
Participants were adults with sciatica for 1–6 months and with moderate or high disability. They were
referred from primary care and musculoskeletal services to outpatient physiotherapy clinics. They received,
at random, either two doses of adalimumab or saline injections. Both groups were referred for a course of
physiotherapy treatment.
Outcomes were measured at the start, and after 6 weeks’ and 6 months’ follow-up. The main outcome
was back pain-related disability. Other outcomes measured leg pain disability, bothersomeness, general
health, anxiety, depression, resource use, predictors of disability and adverse effects.
We planned to recruit 332 participants, with the first 50 taking part in a pilot study. Unfortunately, only
eight participants were recruited from two out of six sites. Of the other four sites, one dropped out, one
failed to complete contract negotiations and two did not sign their contracts until just before trial closure.
In the two sites that did recruit participants, large numbers of invitations were sent, but uptake was poor.
Two sites planned to recruit participants during general practitioner consultations but opened too late
to recruit.
The research question is still an important one to answer. A number of factors contributed to poor
recruitment: contracts, inefficient identification of participants, delays in site set-up and lack of investigator
engagement. Because of this, we were not able to complete the internal pilot or test all of the different
methods for primary care recruitment that we had planned.
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Scientific summary
Background
Sciatica is a severe leg pain usually caused by a ruptured intervertebral disc, the contents of which compress
and irritate a lumbar nerve root. It is common, disabling and costly to the health service and to society.
Current care pathways in the NHS typically involve the prescribing of analgesia by the patient’s general
practitioner (GP) and, if troublesome symptoms persist, referral for physiotherapy in community-based
physiotherapy services, musculoskeletal interface services or secondary care spinal clinics. If pain persists,
patients are referred for more invasive treatment, such as epidural corticosteroid injection, and 5–15% of
patients eventually need disc surgery.
Sciatica caused by lumbar nerve root pain is usually caused by a prolapsed intervertebral disc, not only
because of compression of the nerve root, but also as a result of the release of proinflammatory factors
from the damaged disc, such as tumour necrosis factor alpha (TNF-α). Biological agents, such as the
monoclonal antibodies infliximab (AbbVie, Maidenhead, UK) and adalimumab (Humira®, AbbVie Ltd,
Maidenhead, UK), bind specifically to TNF-α receptors and may have beneficial effects on the inflamed nerve
root in sciatica. A network meta-analysis of different treatment strategies for sciatica found that biological
agents had the highest probability of being best, but with wide confidence intervals. A meta-analysis of
biological agents for sciatica compared with placebo combined six randomised controlled trials (RCTs) and
one non-RCT, and found that biological agents resulted in reduced leg pain intensity in the short term and
increased global effects in the medium term. However, these findings were no longer statistically significant
when studies were restricted to RCTs. Although there was insufficient evidence to change practice from these
reviews, there was sufficient evidence to suggest that a definitive RCT was warranted. This systematic review
did not identify any economic evaluations. Although these treatments are costly, they may be cost-effective
if they reduce the need for more expensive treatments such as disc surgery. In addition, when their patent
expires, cheaper biosimilar drugs may be developed and used in their place. Adalimumab is administered by
subcutaneous injection, but infliximab confers the additional expense of intravenous injection. We used
adalimumab because of its ease of administration and, in order to provide a therapeutic effect lasting
1 month, two subcutaneous injections were given 2 weeks apart. In order to initiate a rapid response, we
used the typical starting dosage when treating psoriasis or Crohn’s disease of 80 mg followed by 40 mg.
Objectives
1. To evaluate the clinical effectiveness of subcutaneous injections of adalimumab plus physiotherapy
compared with a placebo injection of 0.9% sodium chloride plus physiotherapy for patients with
sciatica in whom first-line primary care treatment had failed. We planned to identify potential
participants during primary care consultation, after referral to musculoskeletal service or following a
practice database search.
The primary effectiveness outcome was sciatica-related health status using the Oswestry Disability Index
(ODI). Secondary effectiveness outcomes included pain intensity, location, duration and anticipated
trajectory; the risk of poor outcome; psychological measures including fear of movement, self-efficacy,
anxiety and depression; employment status; and adverse effects.
2. To evaluate, from a health service and personal social care perspective, the cost-effectiveness of
subcutaneous injections of adalimumab plus physiotherapy compared with a placebo injection of 0.9%
sodium chloride plus physiotherapy for patients with sciatica in whom first-line primary care treatment
had failed. The primary economic outcome was the incremental cost per quality-adjusted life-year
(QALY) gained. QALYs would be estimated by administering the EuroQol-5 Dimensions, 5-level version
(EQ-5D-5L) at each follow-up visit.
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Methods
Design
Pragmatic, multicentre RCT with blinded participants and clinicians, and an outcome assessment and
statistical analysis with concurrent economic evaluation and internal pilot.
Main centres
The RCT aimed to recruit from six sites overseen by five collaborating centres in North Wales, London,
Keele, Nottingham and Cardiff.
Selection and withdrawal of subjects
Each collaborating centre would oversee a number of patient identification centres, which consisted of
general medical practices and local musculoskeletal services. Patients would be identified in three ways:
1. by their GP
2. following a search of the general practice patient record database
3. after referral to local musculoskeletal services.
Research clinic
Patients were invited to participate by letter. Those who were interested were contacted by telephone
and, if they fitted the inclusion criteria, were given an appointment in a research clinic run by a research
physiotherapist. At this research clinic all potential participants were assessed by the research physiotherapist
for eligibility. If eligible, participants had blood tests, tuberculosis screening, biological agents counselling
and magnetic resonance imaging (MRI) to exclude serious spinal pathology. A second clinical assessment by
the research physiotherapist 2–3 weeks later assessed if they were still eligible. If they were, informed
consent was obtained for trial entry and randomisation.
Inclusion criteria
l Aged ≥ 18 years.
l Clinical features of sciatica.
l Leg pain worse or as bad as back pain.
l Unilateral leg pain approximating a dermatomal distribution (contralateral buttock pain permitted if it
did not extend below the inferior gluteal margin).
l One of the following:
¢ positive neural tension test, such as the straight-leg raise test restricted to < 50° by leg pain,
positive femoral stretch test, muscle weakness or loss of tendon reflex affecting one myotome
¢ loss of sensation in a dermatomal distribution.
l Persistent symptoms for at least 4 weeks and < 6 months despite first-line treatment in primary care.
l Moderate to high severity (score of ≥ 30 points) on the ODI.
l Female partners of sexually active male participants should use adequate contraceptives for at least
5 months after the last injection. Female participants should have a negative urine pregnancy test
within 2 weeks prior to randomisation, unless they were post menopause or had had a sterilisation
operation. Sexually active men of female participants must also use adequate contraceptive methods.
Exclusion criteria
l Unable to perform MRI.
l Serious spinal pathology.
l Incidental serious pathology identified by MRI.
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l Neurological deficit involving muscle weakness requiring an urgent spinal surgery assessment
(e.g. foot drop).
l Widespread pain throughout the body including the upper limb.
l Prior use of biological agents targeting TNF-α within the previous 6 months.
l Previous lumbar spinal surgery.
l Contraindications to adalimumab injection, including serious infection such as active or latent
tuberculosis, transplanted organ, demyelinating disorders, malignancy, cardiac failure, low white cell
count and pregnancy.
l Pregnancy or breastfeeding (women must not breastfeed for at least 5 months after the last
adalimumab injection).
l Unable to communicate in English or Welsh.
l Unable or unwilling to give informed consent.
Randomisation
Randomisation was achieved by secure web access to the remote randomisation system at the North
Wales Organisation for Randomised Trials in Health at Bangor University, and was performed by a dynamic
adaptive randomisation algorithm to protect against subversion while ensuring that the trial maintained
good balance to the allocation ratio of 1 : 1 both within each stratification variable and across the trial.
Participants were stratified by (1) treatment centre and (2) presence of neurological signs (motor weakness
or sensory loss).
Subcutaneous injections
All participants were randomised to receive two doses of subcutaneous injection 2 weeks apart in the
posterior thigh. The intervention group received 80 mg of adalimumab followed by 40 mg. The control
group received 0.9% sodium chloride in an equivalent volume to the intervention group.
Concurrent physiotherapy
Both groups received a concurrent course of physiotherapy provided over a period of 12 weeks. The
number of sessions provided was determined by participant and therapist preference, and also response to
treatment. We aimed to capture and describe these aspects of physiotherapy treatment as part of the trial.
Clinical management of persistent symptoms
Once the participants had completed their course of physiotherapy, if their symptoms had settled or were
improving, no further intervention was organised. They were discharged to the care of their GP and
followed up by the research team as described in this protocol. If troublesome symptoms persisted, then
further treatment was planned as appropriate by referral to musculoskeletal interface clinics or secondary
care specialists according to local arrangement in each of the centres.
Internal pilot trial
This aimed to rehearse the procedures and logistics to be undertaken in the main trial. It would assess the
feasibility of the arrangements for delivering the interventions, recruitment rate and initial retention rate.
The internal pilot was based on the first 50 participants recruited into the trial. The stopping criteria at the
end of this internal pilot would be recruitment that failed to reach 80% of the planned recruitment rate
target, dropouts up until the 6-week postal questionnaire assessment exceeding 20%, or more than one
centre failing to commence recruitment.
Primary outcome
The primary clinical outcome was back pain-specific disability using the ODI, measured at 12 months.
The primary economic outcome was the incremental cost per QALY gained, estimated by administering the
EQ-5D-5L at each follow-up visit.
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Outcome measures
Condition-specific outcomes
l Back pain-specific disability using the ODI.
l Leg pain-related functional disability using the leg pain version of the Roland–Morris Disability
Questionnaire.
l Leg pain interference using the Sciatica Bothersomeness Index.
l Pain location using a pain manikin.
Generic outcomes
l Health utility using the EQ-5D-5L.
l Global assessment of change since baseline.
Psychological outcomes
l Anxiety and depression using the Hospital Anxiety and Depression Scale.
Use of health care and social care services
l Resource Use Questionnaire.
Process measures (potential predictors and mediators of outcome)
l Risk of persistent disabling pain (STarT Back screening tool).
l Pain trajectory (based on a single question).
l Pain Self-Efficacy Questionnaire.
l Fear avoidance beliefs (Tampa Scale of Kinesiophobia).
Follow-up
The outcomes would be collected at baseline, and after 6 weeks’, 6 months’ and 12 months’ follow-up.
The baseline was administered by research physiotherapists. We would send postal questionnaires at
6 weeks’ and at 6 and 12 months’ follow-up.
Statistics
Sample size
From the weighted mean difference in our previous meta-analysis, we found a relative improvement of
8 points in the ODI at 6 months’ follow-up in the group receiving biological agents compared with placebo,
with a standard deviation of 16 points, giving an effect size of 0.5. To detect a more conservative effect size
of 0.4 with 90% power, with a significance level of 5% for a two-tailed t-test, a sample size of 133 in
each treatment group would be needed. We aimed for a 90% return rate of the final questionnaires, but
for a more conservative retention rate of 80%, 332 participants would need to be recruited.
Data analysis
All data were anonymised and coded so that data collection and statistical analysis would be blinded to
treatment allocation and performed on a ‘treatment as allocated’ principle.
The main outcome variable would be the ODI measured at 12 months. A linear mixed-model approach
for repeated measures would be used to assess the effects of time, group and time × group. Secondary
continuous outcome variables would be assessed in a similar way, with the exception of time to referral for
surgery, which would be assessed from trial entry (this is the date of second consent) using Kaplan–Meier
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survival analyses and the log-rank test. Dichotomous variables would be explored using logistic regression.
These analyses would be repeated using prespecified participant subgroups (including the presence of
neurological deficit on entry to the trial and MRI findings).
Economic analysis
The health economic analysis would adopt the perspective of the NHS and personal social services
and, additionally, indirect costs [e.g. time off work (secondary analysis)]. Costs would include those of
treatment, tests, procedures and investigations, and contact with primary and secondary care services and
personal social services. Resource use would be obtained from participants’ self-reporting of resource use,
captured by questionnaire administration. Unit cost data would be obtained from standard sources. The
primary economic outcomes would be the incremental cost per QALY gained, estimated by administering
the EQ-5D-5L at each follow-up point. Non-parametric bootstrapped 95% confidence intervals would be
estimated (10,000 replicates). Total costs would be combined with QALYs to calculate incremental
cost–utility ratios. Estimates of incremental cost-effectiveness ratios would be compared with the £20,000
to £30,000 per QALY threshold of cost-effectiveness, and a range of one-way sensitivity analyses would be
conducted to assess the robustness of the analysis. Multivariate sensitivity analyses would be applied when
interaction effects were suspected. The joint uncertainty in costs and benefits would be considered
through the application of bootstrapping and the estimation of cost-effectiveness acceptability curves.
Results
Following initial delays finalising the trial contract with the funder, approvals were obtained with only
small delays in the timetable. There were much longer delays negotiating subcontracts with sites. The
contract negotiation in one site was never completed because of ongoing discussion about roles and
responsibilities, and one site withdrew because the principal investigator had safety concerns of the initial
dose. Only two sites recruited participants. In one site there were delays in recruiting from secondary care
populations and delays in setting up primary care recruitment. In the other site, there were delays setting
up the site, difficulties recruiting research physiotherapists and a poor rate of recruitment following the
postal invitation to participate.
Although large numbers of invitations were sent to potential participants (n = 1546), there was a low rate
of uptake with only 25 patients (2%) seen for an initial assessment, and eight patients (32%) were
entered into the trial. Recruitment was improving just before the trial was closed, with five potential
participants ready to be recruited within the following month.
Conclusions
The research question is still important to answer but, because of the lack of trial results, we cannot make
any recommendations for future practice. The main failure was as a result of problems with contracts.
Because of this, we were unable to complete the internal pilot study. There may be insufficient equipoise
around the question of adalimumab for sciatica among patients and some clinicians, which could be
addressed with qualitative research. The two-stage recruitment process was complicated and not feasible.
We had planned to test other methods of primary care recruitment, but unfortunately the trial closed
before we were able to do so.
A trial of biological therapy in patients with sciatica still needs to be done, but would require a clearer
contracting process, qualitative research to ensure that patients would be willing to participate and simpler
recruitment methods.
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Trial registration
This trial is registered as ISRCTN14569274.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Sciatica is a symptom defined as unilateral, well-localised leg pain, with a sharp, shooting or burningquality, which approximates to the dermatomal distribution of the sciatic nerve down the posterior
lateral aspect of the leg, and normally radiates to the foot or ankle. It is often associated with numbness or
paraesthesia in the same distribution.1 Sciatica is an important clinical problem for the NHS. Although
prevalence rates vary widely between studies, in a trial that used a clinical assessment to establish the
presence of sciatica, the point prevalence in the general population aged 30–64 years was 4.8%.2 Some
cohort studies have found that most cases resolve spontaneously, with 30% of patients having persistent
troublesome symptoms at 1 year, with 20% of the total out of work.3,4 However, another cohort found
that 55% still had symptoms of sciatica 2 years later, and 53% after 4 years (which included 25% who
had recovered after 2 years but had relapsed again by 4 years).5 Current care pathways in the NHS typically
involve the prescribing of analgesia by the patient’s general practitioner (GP) and, if troublesome symptoms
persist, referral for physiotherapy either in community-based physiotherapy services, musculoskeletal
interface services or secondary care spinal clinics. If pain persists, patients are referred for more invasive
treatment, such as epidural corticosteroid injection and eventually disc surgery.6 However, the evidence for
most of these non-surgical treatments is poor;7 new treatment strategies are needed. At present between
5% and 15% of patients with sciatica undergo disc surgery.3,4 In the NHS in England in 2013/14, 8330
lumbar discectomies were performed.8 Based on a Dutch trial that indicated that the cost of sciatica to
society represents 13% of all back pain-related costs, the annual impact on the UK economy is £268M in
direct medical costs and £1.9B in indirect costs (inflated from 1998 figures).9
Sciatica caused by lumbar nerve root pain usually arises from a prolapsed intervertebral disc,3 not only
from compression of the nerve root,10 but also the release of proinflammatory factors from the damaged
disc.11,12 Internal disc rupture that does not result in prolapse can also induce disabling radicular pain,13 and
the degree of disc displacement, nerve root enhancement and neural compression on magnetic resonance
imaging (MRI) does not correlate with sciatic symptoms.14 Corticosteroids have been used in an attempt to
reduce the inflammation of the affected nerve root. Intramuscular corticosteroid injections have been tried,
but two randomised controlled trials (RCTs) comparing them with placebo have found no evidence of
efficacy.15 Injection of corticosteroid into the epidural space should increase the amount of steroid reaching
the affected nerve root, and it is a commonly used intervention in the NHS. However, systematic reviews of
epidural steroid injections have reached conflicting views with regard to their efficacy compared with
placebo, and their effectiveness compared with other treatments.7,15–17 They also require to be administered
by a specialist, usually as a hospital day case procedure, which increases their cost of administration. Other,
less invasive, treatments to reduce inflammation in the affected nerve root are needed. The most important
proinflammatory factor released from the prolapsed intervertebral disc is tumour necrosis factor alpha
(TNF-α).11,12 The monoclonal antibodies infliximab and adalimumab (Humira®; AbbVie Ltd, Maidenhead, UK)
target TNF-α and are increasingly used to control inflammatory disease such as psoriasis, Crohn’s disease
and rheumatoid arthritis. These so-called ‘biological agents’ bind specifically to TNF-α receptors on the
cell surface and modulate biological responses that are induced or regulated by TNF-α, including the
inflammatory process.18 They may also have beneficial effects on the inflamed nerve root in sciatica,19
and have the additional advantage of being administered by intravenous (infliximab) or subcutaneous
(adalimumab) injection in a hospital outpatient clinic, rather than by epidural injection as a hospital day case.
This research followed the recommendations of a Health Technology Assessment (HTA)-funded systematic
review of management strategies for sciatica.20 In this review the clinical effectiveness of different
treatment strategies for sciatica were compared simultaneously using network meta-analysis. Network
meta-analysis allows treatment strategies to be ranked in terms of clinical effectiveness with an estimate
of the probability that each strategy is best, and provides estimates for all possible pairwise comparisons,
based on both direct and indirect evidence. In terms of overall recovery or global effect, biological agents
had the highest probability (0.5) of being best, with an odds ratio (OR) compared with inactive control
of 16, but with very wide 95% credible intervals (CrIs) of 0.6 to 1002, reflecting the small number of
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included studies and lack of data that were available to inform these effect estimates. A CrI is a Bayesian
confidence interval (CI). There were large but non-statistically significant effect estimates in favour of
biological agents compared with the other treatment strategies, including traction (OR 13, 95% CrI 0.4 to
943), exercise therapy (OR 15, 95% CrI 0.4 to 1085) and passive physical therapies (OR 14, 95% CrI 0.5 to
975). In terms of pain intensity, biological agents had the second highest probability of being best (0.2),
and were found to be statistically significantly better than the inactive control, but with wide CrIs,
with a weighted mean difference (WMD) of –22 (95% CrI –36 to –8) compared with an opioid WMD of
–31 (95% CrI –53 to –9) and a non-opioid analgesia WMD of –18 (95% CrI –33 to –2).
Following this HTA review we updated the literature search of biological agents for sciatica (from inception
to February 2012).21 We identified seven RCTs, one non-RCT and one historical cohort trial. We combined
the results of six RCTs22–27 and one non-RCT28 comparing biological agents with placebo in meta-analyses.
We found that biological agents resulted in better global effects in the short term (around 6 weeks’
follow-up) (OR 2.0, 95% CI 0.7 to 6.0), medium term (around 6 months’ follow-up) (OR 2.7, 95% CI 1.0
to 7.1) and long term (≥ 12 months’ follow-up) (OR 2.3, 95% CI 0.5 to 9.7); improved leg pain intensity in
the short term (WMD –13.6, 95% CI –26.8 to –0.4) and medium term (WMD –7.0, 95% CI –15.4 to 1.5),
but not the long term (WMD 0.2, 95% CI –20.3 to 20.8); and improved Oswestry Disability Index (ODI)
score in the short term (WMD –5.2, 95% CI –14.1 to 3.7), medium term (WMD –8.2, 95% CI –14.4 to
–2.0) and long term (WMD –5.0, 95% CI –11.8 to 1.8). It should be noted that there was heterogeneity
in the leg pain intensity and ODI results, and improvements were no longer statistically significant when
studies were restricted to RCTs. There was a reduction in the need for disc surgery, which was not
statistically significant, limited evidence for improved employment outcomes and no difference in the
number of adverse effects. There was limited evidence that a biological agent was superior to intravenous
corticosteroids (one historical cohort trial),29 but not compared with epidural corticosteroid (two RCTs).27,30
We concluded that there was some evidence of efficacy, but a paucity of evidence for clinical effectiveness
for biological agents. Although there was insufficient evidence to change practice, there was sufficient
evidence to suggest that a definitive RCT was warranted.
As part of the HTA review of management strategies for sciatica,20 a decision-analytic model was developed
to estimate the relative cost-effectiveness of these different strategies. Three different treatment pathways
were compared. The first pathway was primary care treatments alone (including the categories usual care,
activity restriction, advice, non-opioid and opioid analgesia). The second pathway was stepped care starting
with primary care treatments and, for those who did not improve, intermediate care treatment (exercise
therapy, passive physical therapy, traction, manipulation, acupuncture and biological agents), epidural
steroid injections then finally disc surgery. The third pathway was immediate referral to disc surgery
following failed primary care management. The stepped care pathway was the most effective, with the
most successful treatment strategy being non-opioid analgesia in primary care, followed by biological
agents in intermediate care, followed by epidural corticosteroid injection and disc surgery. The place for
biological agents in the therapeutic pathway is as a therapeutic option to be used by intermediate care
services in patients for whom primary care treatment has failed, with the potential to reduce the need for
more invasive treatments.
In summary, biological agents have the potential to reduce inflammation and nerve root pain in patients
when primary care management has not relieved symptoms, but might they benefit the NHS? Apart from
the economic model developed for the HTA review of management strategies for sciatica,31 there have
been no economic evaluations of these agents. Although they might be beneficial for patients with sciatica,
these agents are expensive costing £352 for 40 mg of adalimumab and £420 for 100 mg of infliximab.32
Adalimumab is administered by subcutaneous injection, but infliximab confers the additional expense of
intravenous injection. We intended to use adalimumab because of its ease of administration and, in order to
provide a therapeutic effect lasting 1 month, two subcutaneous injections would be given 2 weeks apart.
In order to initiate a rapid response, we used the typical starting dosage when treating psoriasis or Crohn’s
disease of 80 mg followed by 40 mg.18 Despite their cost, they may be cost-effective if shown to be
sufficiently clinically effective and/or they reduce the need for more expensive treatments such as disc
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surgery, the average unit cost of which is between £3676 and £4971.32 When the patent for adalimumab
expires, it may result in the development of cheaper biosimilar drugs that can be used in its place. From
searches of databases of current trials (inception to November 2013), we have not identified any large RCTs
with a concurrent economic evaluation in a NHS setting.
Trial objectives
1. To evaluate the clinical effectiveness of subcutaneous injections of adalimumab plus physiotherapy
compared with a placebo injection of 0.9% sodium chloride plus physiotherapy for patients with
sciatica who have failed first-line primary care treatment. Potential participants were planned to be
identified during primary care consultation, after referral to musculoskeletal service or following a
practice database search.
The primary effectiveness outcome was sciatica-related health status using the ODI.33 Secondary
effectiveness outcomes included pain intensity, location, duration and anticipated trajectory; the risk of
poor outcome; psychological measures, including fear-avoidance beliefs, self-efficacy, anxiety and
depression; employment status; and adverse effects.
2. To evaluate the cost-effectiveness of subcutaneous injections of adalimumab plus physiotherapy
compared with a placebo injection of 0.9% sodium chloride plus physiotherapy for patients with
sciatica who have failed first-line primary care treatment from a health service and personal social care
perspective. The primary economic outcome was the incremental cost per quality-adjusted life-year
(QALY) gained. QALYs would be estimated by administering the EuroQol-5 Dimensions, 5-level version
(EQ-5D-5L)34 at each follow-up visit.
Trial flow
The flow chart to show the different stages of the trial is presented in Figure 1. The flow chart to show the
experience of the participant through the trial is in Figure 2.
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Severe symptoms, referral for MRI and
first consent
Primary care treatment failed or referred to local musculoskeletal service
(> 4/52, < 6/12 duration, severe symptoms or recurrence), screened for
eligibility criteria and trial information sent
Physiotherapy clinical assessment and screening 
Serious spinal pathology
excluded
MRI findings used in planned
subgroup analysis
Mild symptoms: advice
Discharge back to GP care
Remote
randomisation
Adalimumab injection 80 mg then
40 mg after 2 weeks (subcutaneous) 
(n = 166)
Concurrent physiotherapy
intervention
Placebo injection repeated after 
2 weeks 
(n = 166)
Concurrent physiotherapy
intervention
MRI scan, TB screening, biological agent
counselling, and blood and urine tests
Postal outcome measures at 6 weeks 
Symptoms settled
Discharge back to GP care
Symptoms persist
Further treatment planned with MRI
Semistructured telephone interviews at 12 months 
(n = 266)
Postal outcome measures at 6 months 
Second clinical assessment, second consent,
baseline outcome measurement 
(n = 332)
Postal outcome measures at 12 months 
(n = 266)
Telephone contact by research physiotherapist to determine potential
eligibility. If eligible, appointment given for research physiotherapy clinic
FIGURE 1 Consolidated Standards of Reporting Trials flow chart. MRI, magnetic resonance imaging;
TB, tuberculosis.
BACKGROUND
NIHR Journals Library www.journalslibrary.nihr.ac.uk
4
If symptoms settle: discharged and GP informed If symptoms persist: referred to spinal clinic
Potential participants identified during primary care consultation, after referral to local musculoskeletal 
service or following a practice database search. Invitation letter sent by GP
Form indicating willingness to participate returned to research team
Telephone contact by research physiotherapist to determine potential eligibility. If eligible, appointment
given for research physiotherapy clinic
First clinical assessment in research physiotherapy clinic to assess eligibility. Initial consent obtained
Blood and urine test, TB screening including CXR and biological agent counselling by research nurse; 
MRI scan and reporting
Rheumatologist confirms participant’s suitability. Two subcutaneous injections administered by
rheumatology nurse
Second clinical assessment in research physiotherapy clinic to determine if still eligible and confirm that
counselling, TB screening, MRI and blood tests have been performed and are satisfactory. Second informed
consent obtained. Baseline questionnaire completed by patient. Web-based randomisation
Concurrent physiotherapy intervention
One subcutaneous injection administered by rheumatology nurse 2 weeks later
6-week postal questionnaire to be completed by patient; additional questionnaire sent if no response
Physiotherapy intervention completed
6-month follow-up by postal questionnaire to be completed by patient
Additional questionnaire sent if no response
12-month follow-up by postal questionnaire to be completed by patient
Additional questionnaire sent if no response
Telephone interview to collect minimal data set if no response
Telephone interview for brief semistructured interview and to collect minimal data set if no response
FIGURE 2 Participant flow chart. CXR, chest radiography; MRI, magnetic resonance imaging; TB, tuberculosis.
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Chapter 2 Methods
Design
Pragmatic, multicentre RCT with blinded participants, clinicians, outcome assessment and statistical analysis
with concurrent economic evaluation and internal pilot.
Main centres
The RCT was planned to recruit from sites overseen by five collaborating centres in North Wales, London,
Keele, Nottingham and Cardiff.
Selection and withdrawal of participants
Each collaborating centre oversaw one or more treatment sites that were delegated responsibility for
delivering the interventions. Each treatment site had a number of patient identification centres, which
consisted of general medical practices and local musculoskeletal services. The target population was adults
with suspected sciatica for whom primary care treatment had failed. This was defined as troublesome
symptoms (e.g. back and leg pain, pins and needles, numbness in leg, weakness), persisting for > 4 weeks
and < 6 months. As the recruitment process took at least 4 weeks before participants were randomised,
we did not have a lower time limit for duration of symptoms when identifying the target population and
had an upper time limit of 20 weeks. These patients were identified in three ways:
1. by their GP
2. following a search of the general practice patient record database
3. after referral to local musculoskeletal services.
General practitioner referral
Patients identified during the primary care consultation with suspected sciatica were provided with
information about the trial and invited, if interested, to return the reply slip to the research team in the
pre-paid envelope. In North Wales and Keele, the primary care database displayed ‘pop-up’ screen
messages to remind GPs about the study when potential patients were consulted.
Following a search of the general practice patient record database
Potential participants were identified by regular searches of the general practice patient record database
by the practice management staff, directed by research officers from either the Health and Care Research
Wales workforce or the local Clinical Research Network in England. The database was searched for
diagnostic codes for sciatica. Participants were excluded if they had a known serious spinal pathology or a
contraindication to adalimumab injection, such as serious infection [e.g. active or latent tuberculosis (TB)],
transplanted organ, demyelinating disorders, malignancy, cardiac failure, low white blood cell count or
pregnancy. Those identified as potentially eligible were invited to participate by a written invitation from
their GP on the practice’s headed notepaper, and hand signed by a GP. Those who were interested
returned the reply slip to the research team in the pre-paid envelope.
Local musculoskeletal services
Potential participants with suspected sciatica were also identified from referrals to local musculoskeletal
services. Those identified were invited to participate by a written invitation from the local service on headed
notepaper. Those who were interested returned the reply slip to the research team in the pre-paid envelope.
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The centres in North Wales, Keele and Cardiff planned to identify and recruit participants in three ways:
by their GP, following a search of the general practice patient record database or after referral to local
musculoskeletal services. Nottingham and London planned to recruit and identify participants who had
been referred to their local musculoskeletal services.
Telephone contact by the research physiotherapist
All those who had contacted the research team to state that they were interested in participating were
sent a participant information sheet and were contacted by telephone by the research physiotherapist.
The telephone call determined if they had unilateral leg pain and, if back pain was present, that leg pain
intensity was worse than, or as bad as, the back pain. It also determined whether or not symptoms had
persisted for > 20 weeks (to allow participants to be within the 6-month limit at randomisation). Finally,
the telephone call allowed them to discuss any questions that they may have had about the study or
their symptoms.
Research clinic
Those who satisfied the eligibility criteria were given an appointment slot in a research clinic run by
research physiotherapists. At this research clinic all potential participants were assessed by the research
physiotherapist for eligibility. Eligible participants who gave initial consent were registered and provided
with a unique participant identification number. The following data were recorded on case report forms:
l demographic details such as age, sex, height and weight
l clinical findings such as pain location, pain duration, other presenting complaints, straight-leg raise test
(left and right), femoral stretch test, muscle power, pinprick and light-touch sensation, quadriceps and
Achilles tendon reflexes.
The research physiotherapist arranged for the participant to have the following blood tests taken by the
phlebotomist to exclude haematological and biochemical abnormalities: full blood count, urea and electrolytes,
estimated glomerular filtration rate, liver function test and glycosylated haemoglobin. The participant received
TB screening in accordance with local practice and biological agents counselling. The research physiotherapist
then arranged an appointment for MRI to exclude serious spinal pathology. All of these tests were completed
within 2–3 weeks of the initial clinic visit and were recorded on the case report forms. The presence or
absence of a disc prolapse on MRI was not to be used as an inclusion criterion, because the degree of disc
displacement, nerve root enhancement or neural compression found on MRI does not correlate with sciatic
symptoms.14 MRI was reported by the local radiologist using a trial-specific standard operating procedure.
The initial report stated whether or not the participant had serious spinal pathology that required a different
treatment. A full MRI report was available only after completion of the study. Individual results were made
available if a report was needed in an emergency, or if a spinal surgery referral was contemplated.
The research physiotherapist ensured that the participant received all the required tests. If there was any issue
that required action, then the participant’s referring GP or musculoskeletal clinician was informed. When MRI
had excluded serious spinal pathology, participants were contacted by the research physiotherapists either by
telephone or post to attend the research clinic, where they received a second clinical assessment by the
research physiotherapist, 2–3 weeks after their initial visit, to assess if they were still eligible. If they were still
eligible, further consent was obtained for trial entry and randomisation when they were provided with a
unique participant identification number. Table 1 shows the schedule of forms and procedures.
METHODS
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TABLE 1 The Subcutaneous Injection of Adalimumab Trial compared with Control (SCIATiC) protocol schedule of forms and procedures
Time point
Study period Follow-up period
Enrolment
Randomisation
(within 2–3 weeks
of registration)
Treatment visit 1
(within 3 days of
randomisation) Treatment visit 2 6 weeks 6 months 12 months
Eligibility ✗ ✗
Informed consent ✗ ✗
Registration to trial ✗
FBC ✗
Urine pregnancy test ✗
U&E ✗
TB screening ✗
MRI ✗
MRI reportinga ✗a ✗a
Eligibility confirmed ✗ ✗
Randomisation ✗
Subcutaneous injection of allocated treatment ✗ ✗
Physiotherapy treatment ✗ ✗
ODI ✗ ✗ ✗ ✗
EQ-5D-5L ✗ ✗ ✗ ✗
RMDQ ✗ ✗ ✗ ✗
SBI ✗ ✗ ✗ ✗
STarT Back Screening Tool ✗
PSEQ ✗ ✗ ✗ ✗
HADS ✗ ✗ ✗ ✗
TSK ✗ ✗ ✗ ✗
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TABLE 1 The Subcutaneous Injection of Adalimumab Trial compared with Control (SCIATiC) protocol schedule of forms and procedures (continued )
Time point
Study period Follow-up period
Enrolment
Randomisation
(within 2–3 weeks
of registration)
Treatment visit 1
(within 3 days of
randomisation) Treatment visit 2 6 weeks 6 months 12 months
RUQ ✗ ✗ ✗ ✗
Pain outcome ✗ ✗ ✗ ✗
Manikin pain diagram ✗ ✗ ✗ ✗
Pain duration ✗
Pain trajectory ✗
Days of work ✗ ✗ ✗ ✗
Global assessment of change ✗ ✗ ✗
Adverse events ✗ ✗ ✗ ✗ ✗
FBC, full blood count; HADS, Hospital Anxiety and Depression Scale; PSEQ, Pain Self-Efficacy Questionnaire; RMDQ, Roland–Morris Disability Questionnaire; RUQ, Resource Use
Questionnaire; SBI, Sciatica Bothersomeness Index; TSK, Tampa Scale of Kinesiophobia; U&E, urea and electrolytes.
a The findings of the MRI will only be available to the participant’s treating clinician after completion of the study. Individual results will be made available if a report is needed in an
emergency, or if a spinal surgery referral is being contemplated and will be shared with the clinical team, referring GP and the musculoskeletal clinician.
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Inclusion criteria
l Aged ≥ 18 years.
l Clinical features of sciatica.
l Leg pain worse or as bad as back pain, elicited by asking the participant.
l Unilateral leg pain approximating a dermatomal distribution (contralateral buttock pain permitted if it
did not succeed the inferior gluteal margin), obtained by asking the participant.
l One of the following:
¢ positive neural tension test, such as straight-leg raise test restricted to < 50° by leg pain; positive
femoral stretch test; muscle weakness or loss of tendon reflex affecting one myotome
¢ loss of sensation in a dermatomal distribution.
l Persistent symptoms for at least 4 weeks and < 6 months despite first-line treatment in primary care,
obtained by asking the participant.
l Moderate to high severity (score of ≥ 30 points on the ODI).33
Female partners of sexually active male participants had to use adequate contraception for at least
5 months after the last injection. Female participants were required to have had a negative urine pregnancy
test within 2 weeks prior to randomisation, unless they were post menopause or had been sterilised.
Sexually active male partners of female participants were also required to use adequate contraceptive
methods. The researcher ensured that the risks, and consequences, of not using adequate contraception
were fully understood by the participants and provided information and pathways as deemed necessary.
Exclusion criteria
l Symptoms persisting for > 6 months (elicited by asking the participant).
l A previous episode of sciatica in the last 6 months.
l Unable to undergo MRI (e.g. magnetic metal implants, potential metallic intraocular foreign bodies,
claustrophobia, extreme obesity), obtained from the medical records and by asking the participant.
l Serious spinal pathology (including cauda equina syndrome, malignancy, recent fracture, infection or
very large disc prolapse), which might require an urgent spinal surgery opinion, identified from
participants’ previous medical history in their medical records or from MRI.
l Incidental serious pathology identified by MRI (e.g. adrenal tumour).
l Neurological deficit involving muscle weakness requiring an urgent spinal surgery assessment
(e.g. foot drop).
l Widespread pain throughout the body including the upper limb.35 Pain was considered widespread
when all of the following were present: pain in the left side of the body, pain in the right side of the
body, pain above the waist and pain below the waist. Axial skeletal pain (cervical spine or anterior
chest or thoracic spine or low back) had also to be present.
l Prior use of biological agents targeting TNF-α within the previous 6 months obtained from the medical
records and by asking the participant.
l Previous lumbar spinal surgery, elicited from the medical records and by asking the participant.
l Contraindications to adalimumab injection including serious infection such as active or latent TB,
transplanted organ, demyelinating disorders, malignancy, cardiac failure, low white blood cell count,
pregnancy (determined from the medical records, the results of investigations and by asking
the participant).
l Pregnant or breastfeeding (women must not breastfeed for at least 5 months after the last
adalimumab injection).
l Unable to communicate in English or Welsh.
l Unable or unwilling to give informed consent.
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Informed consent
At the initial physiotherapy clinic, the research physiotherapist determined preliminary eligibility, explained
the nature of the trial and gave a repeat participant information sheet. The participant information
sheet had been approved by the ethics committee and set out all of the key information, including the
practicalities of the trial, the possible benefits and risks, and trial assessments. Participants were registered
onto the trial and details were recorded on a database and a screening log at each of the trial treatment
sites, and were assigned a unique participant identification number. Anonymised details labelled with the
unique participant identification number were transferred to a separate database in the trials unit, which
was used for recording all of the trial data. This ensured that the outcome measurement and statistical
analysis would be performed blind to treatment allocation. All databases were password protected. The
participant consent forms were stored in a locked filing cabinet in each treatment site. Clinical findings
were recorded on case report forms.
Eligible participants who gave initial consent had blood tests to exclude haematological and biochemical
abnormalities (full blood count, urea and electrolytes, estimated glomerular filtration rate, liver function
test, glycated haemoglobin levels). They received TB screening, including plain chest radiography,
biological agents counselling and MRI to exclude serious spinal pathology within 2–3 weeks of their initial
visit. When MRI had excluded serious spinal pathology, and TB screening, a pregnancy test (in the case of
eligible women) and biological agent counselling had been completed, participants attended a further
appointment with the research physiotherapist. A second clinical assessment was performed and those
who were still eligible were asked to complete a second informed consent form, approved by the ethics
committee. In order to enter the RCT, the participant was randomised by the research physiotherapist
using a remote web-based system. The treatment site sent a letter to each participant’s GP, informing
them of their patient’s participation in the trial and requesting that the GP make a note of this in the
patient’s record. In addition, GPs were asked to inform the trial team if they became aware that the
participant had experienced an adverse event during the trial.
Three copies of the consent form were signed by the participant. The original was kept by the research
team, one copy was kept by the participant and the third was filed in the participant’s hospital medical
records. All participant information sheets, letters of invitation and consent forms were provided in Welsh
and English in the two Welsh centres.
Magnetic resonance imaging
Participants who had given initial informed consent underwent MRI to exclude serious spinal pathology, but
the presence or absence of a disc prolapse was not used as an inclusion criterion. The MRI scans were read
and reported by a local radiologist, using a trial-specific standard operating procedure at each treatment site,
who was independent of the trial team. Only results that showed serious pathology or suspected serious
pathology were revealed to the research team, referring GP and the musculoskeletal clinician, who would then
exclude the participant and refer for urgent assessment. Otherwise, the research team were informed that no
serious spinal pathology was identified. The findings of MRI would be made available to the participant’s
treating clinician only after completion of the study. Individual results were made available if a report was
needed in an emergency, or if a spinal surgery or epidural injection referral was being contemplated, and were
distributed to the clinical team, referring GP and the musculoskeletal clinician. The MRI findings were to be
used in a planned a priori subgroup analysis. For clinical purposes, radiologists from each site provided a
clinical report of the MRI. For the purpose of reporting standardised findings for research, two independent
radiologists reported the MRI findings for all trial participants. The radiologists interpreted the report according
to the MRI findings only.
METHODS
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Tuberculosis screening and biological agent counselling
The screening and counselling protocols used routinely by the rheumatology departments in each of the
treatment sites were used and administered by an experienced rheumatology specialist nurse. All of the
participating centres had access to either a specialist TB clinic or an infectious disease service, where any
identified cases were referred and managed.
Second physiotherapy assessment
Participants attended a second appointment with the research physiotherapist 2–3 weeks after the initial
appointment, after the MRI results had been reported and following TB screening and biological agent
counselling. A second clinical assessment was performed and all the results of the tests performed were
checked. If the participant remained eligible, a second consent form was completed. Participants completed
a baseline questionnaire and were randomised using a remote web-based system. If they no longer fulfilled
the criteria for trial entry, because their symptoms had improved at or below the 30-point threshold on the
ODI, they were given advice about managing their remaining symptoms and discharged back to the care of
their GP. Clinical findings were recorded on case report forms.
Registration
Once the first consent had been obtained, participants’ details were recorded on a database in the trial
centre and each participant was assigned a unique participant identification number. Anonymised details
labelled with the unique participant identification number were transferred to a separate database in the
trials unit, which was used for recording all of the trial data. All databases were password protected. The
participant consent forms were stored in a locked filing cabinet in each treatment site. Participants’ GPs
were informed in writing about their participation in the trial.
Randomisation
After completion of the second consent form and once baseline outcome measures had been collected,
participants were individually randomised. Randomisation to the Subcutaneous Injection of Adalimumab
Trial compared with Control (SCIATiC) was achieved by secure web access to the remote randomisation
system at the trials unit. This system was maintained and monitored independently of the trial statistician
and any trial staff who needed to remain blind to the treatment allocation. In order to protect against
subversion, while ensuring that the trial maintained good balance to the allocation ratio of 1 : 1 both
within each stratification variable and across the trial, the randomisation was performed using a dynamic
adaptive randomisation algorithm.36 Participants were stratified by (1) treatment centre and (2) presence of
neurological signs (motor weakness or sensory loss). The research physiotherapist who obtained informed
consent requested the randomisation code from the web-based randomisation system, the result of which was
e-mailed to the pharmacy and the rheumatology nurse, but not the research physiotherapist. The dispensing
pharmacist logged and dispensed the appropriate injection in line with Medicines and Healthcare products
Regulatory Agency (MHRA) guidelines. The injection was given on the day of randomisation; if this was not
possible, a further appointment was arranged by the research physiotherapist so that the treatment could be
given within 3 days from randomisation.
Withdrawal of participants
Withdrawal from the trial did not affect participants’ medical care, something that was emphasised in the
participant information sheet. Failure to complete any one follow-up assessment did not constitute formal
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withdrawal from the trial, and, unless participants requested complete withdrawal of their data, data were
used to impute values for the analysis. The imputation of missing values ensured that the data set was
utilised to its full power. The full imputation details were prespecified as part of the statistical analysis plan.
Expected duration of trial
We planned to recruit participants over a 20-month period and to follow them up for 12 months.
Subcutaneous injections
All participants were randomised to receive two doses of subcutaneous injection, 2 weeks apart, into the
posterior thigh. The intervention group received 80 mg of adalimumab followed by 40 mg,18 in order to
achieve a therapeutic dose of adalimumab for a period of 4 weeks. The control group received an
equivalent volume of 0.9% sodium chloride.
Injection process
The injections were prescribed by a consultant rheumatologist and administered by a rheumatology
nurse experienced in the administration of these injections. The first injection was given on the same
day as randomisation; if this was not possible, a further appointment was arranged by the research
physiotherapist so that the treatment could be given within 3 days of randomisation. It was not possible to
make the adalimumab and placebo syringes indistinguishable in appearance, nor was it possible to blind
the pharmacy or the rheumatology nurse who administered the injections. Blinding of participants and the
other clinicians was maintained using the following strategies. The rheumatologist wrote a prescription for
‘SCIATiC trial injection’ and was kept blind to treatment allocation. The research physiotherapist who
obtained informed consent requested the randomisation code from a web-based randomisation system.
The randomisation code was not sent to this physiotherapist, but was e-mailed to the pharmacy and the
rheumatology nurse. The rheumatology nurse collected the injection from the pharmacy, which was
transported in an undistinguishable box containing the adalimumab inside its original packaging or the
0.9% sodium chloride-containing ampoules. Communication between the participant and rheumatology
nurse concerning the injection was kept to a minimum, and the rheumatology nurse administered the
injections into the participant’s posterior thigh. The research physiotherapist was not present and did not
communicate with the rheumatology nurse about the injection. In addition, in order to provide reassurance
that other clinicians were not present, a log was kept of all people present in the room when each
injection was administered. All research staff received full training on the blinding procedures. In order to
assess whether or not blinding had been maintained, the participants were asked to complete a five-point
Likert scale that asked if the participant considered the treatment to be:
1. definitely in the 0.9% sodium chloride injection group
2. more likely to be in the 0.9% sodium chloride injection group
3. equally likely to be in the 0.9% sodium chloride injection group or the adalimumab injection group
4. more likely to be in the adalimumab injection group
5. definitely in the adalimumab injection group.
Concurrent physiotherapy
Physiotherapy is usually considered normal practice for those participants who fail to improve with GP
care alone. In this trial we aimed to investigate the clinical effectiveness of adalimumab in addition to
physiotherapy. Current evidence on physiotherapy interventions for participants with sciatica indicates that
METHODS
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specific exercise approaches (directional preference-based exercises or ‘McKenzie’ exercises based on
certain spinal movements with or without manual therapy techniques) seem to relieve pain.37 There was
also evidence that exercise-based physiotherapy treatment added to GP care was beneficial.38 Regimes
including strengthening exercises of the lumbar and pelvic muscles also show some promise in terms of
improvements in this group of participants. In this trial, both groups received a concurrent course of
physiotherapy intervention that could be described as ‘best conservative care’. It was delivered in local
physiotherapy departments by ‘treating’ physiotherapists and not by the ‘research’ physiotherapists who
were carrying out the assessments of eligibility and randomisation. The physiotherapy intervention
consisted of a package of directional preference (McKenzie), strengthening exercises or other exercises,37,38
and manipulative techniques that had been determined by consensus using a panel of extended scope
physiotherapists. Treatments were intended to take into account and address participants’ individual
needs, including clinical monitoring; appropriate advice and reassurance; assessment of psychosocial
obstacles to recovery, such as excessive worrying or unhelpful beliefs about physical activity; and
encouragement of appropriate, gradual return to full function, including work when applicable. The first
session was expected to last approximately 45 minutes, with subsequent sessions lasting 30 minutes each.
The therapy sessions were to be provided over a period of 12 weeks. The number of sessions provided
would be determined by participant and therapist preference, and also response to treatment. We
captured and described these aspects of physiotherapy treatment as part of the trial. The physiotherapy
treatment started at the same time as the injection intervention in both arms of the trial. Participants were
discouraged from receiving any other NHS-based co-intervention until this physiotherapy treatment
had finished.
Clinical management of persistent symptoms
The protocol was designed such that, once the participants had completed their course of physiotherapy,
and symptoms had settled or were improving, then no further intervention would be organised. They were
to be discharged to the care of their GP and followed up by the research team. If troublesome symptoms
persisted, then further treatment could be planned, as appropriate, by referral to musculoskeletal interface
clinics or secondary care specialists according to local arrangement in each of the centres. The plans for
further treatment were at the discretion of the treating clinicians and could include epidural corticosteroid
injections or referral for disc surgery. The full result of MRI was to be made available if a spinal surgery
referral was contemplated. All additional treatments were recorded in detail in a case report form.
Internal pilot trial
The pilot built on previous research in this participant group undertaken by team members,20,21,30,39 which
had already provided information on trial administration, the characteristics of sciatica participants and
the effects of biological treatments from previous studies. The internal pilot was designed to rehearse the
procedures and logistics to be undertaken in the main trial. It was designed to assess the feasibility of
the arrangements for delivering the interventions, recruitment rate and initial retention rate. The internal
pilot would be based on the first 50 participants recruited into the trial. We planned to start recruitment in
two centres (North Wales and London) and then to roll out recruitment in the other three centres over the
following 3 months. We expected the recruitment rate to build up over the first 3 months to the target
rate of four participants per collaborating centre per month. We anticipated that this would take 7
months. The indicative stopping criteria at the end of this internal pilot were recruitment, which failed to
reach 80% of the planned recruitment rate target, dropouts up until the 6-week postal questionnaire
assessment exceeding 20% or more than one centre failing to commence recruiting. Any procedural
changes identified in the pilot would be implemented across all trial sites subject to ethics approval of the
appropriate major amendment. Data from participants in the internal pilot would be automatically rolled
into the main trial data unless the Trial Management Group (TMG) believed that data were incompatible
with the remaining data. No interim analysis at the primary end point (1 year) was proposed and,
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therefore, this internal pilot would not affect the overall power of the trial. Wittes and Brittain’s40 method
would be used for sample size recalculation if required.
Primary outcome
The primary clinical outcome was back pain-specific disability measured using the ODI33 at 12 months.
The primary economic outcome was the incremental cost per QALY gained, estimated by administering the
EQ-5D-5L34 at each follow-up visit.
Outcome measures
Condition-specific outcomes
l Back pain-specific disability using the ODI.33
The ODI is an outcome assessment tool that is used to measure a participant’s impairment and quality
of life (i.e. how badly the pain has affected their life). The participant questionnaire contains items
concerning intensity of pain, lifting, ability to care for oneself, ability to walk, ability to sit, sexual
function, ability to stand, social life, sleep quality and ability to travel. Each topic category is followed
by six statements describing different potential scenarios in the participant’s life relating to the topic.
The participant then checks the statement that most closely resembles their situation. Each question
is scored on a scale of 0–5, with the first statement being zero and indicating the least amount of
disability and the last statement scoring 5 and indicating the most severe disability. The index is
converted to a percentage score from 0 to 100. Zero is equated with no disability and 100 with
maximum disability. It was used at the first clinical assessment to assess eligibility and also at the
second clinical assessment to confirm eligibility. If recruited onto the trial, this score was used as the
baseline measurement. It would also be measured at follow-up after 6 weeks, and at 6 and 12 months.
l Leg pain-related functional disability using the leg pain version of the Roland–Morris Disability
Questionnaire (RMDQ).41,42
The RMDQ is a measure of disability in which greater levels of disability are reflected by higher
numbers on a 24-point scale. The RMDQ is a self-administered outcome measure. Participants are
asked to read the list of 24 sentences and place a tick against appropriate questions based on how
they feel each sentence describes them on that day. If the sentence does not describe their symptoms
that day, participants are asked to leave the space next to the sentence blank. The RMDQ is scored by
adding up the number of items checked by the participant. The score can therefore vary from 0 to
24 points. If a participant indicates in any way that an item is not applicable to them, the item is scored
‘no’ (i.e. the denominator remains 24). It was measured at baseline and at 6 weeks’ and 6 and
12 months’ follow-up.
l Leg pain interference using the Sciatica Bothersomeness Index.43
This is an index based on participants reporting symptoms that reflected the trouble the participant is
going through with his/her sciatica symptoms. The index included self-reported ratings of symptom
intensity of leg pain; numbness or tingling in the leg, foot or groin; weakness in the leg/foot; or back
or leg pain while sitting. Each symptom item is rated on a scale from 0 to 6, with 0 being not
bothersome, 3 somewhat bothersome and 6 extremely bothersome. It was measured at baseline and
at 6 weeks’ and 6 and 12 months’ follow-up.
l Pain location using a pain manikin.44
This is a picture of a human figure (manikin) on which pain is indicated by the participant and can be
used to measure musculoskeletal pain. It was used at baseline, 6 weeks’, and 6 and 12 months’
follow-up.
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Generic outcomes
l Health utility using the EQ-5D-5L.34
This is a participant-completed index of health-related quality of life, which gives a weight to different
health states. It consists of five dimensions: mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. Each has five levels of severity (no problems/some/moderate problems/extreme
problems and unable to). It was used at baseline and at 6 weeks’ and 6 and 12 months’ follow-up.
It allowed the calculation of QALYs, using the area under the curve method, which would be used as
part of the economic analysis.
l Global assessment of change since baseline.
The global assessment of change is a measure of changes in levels of pain over a set time period.
It was measured at 6 weeks’ and at 6 and 12 months’ follow-up.
Psychological outcomes
l Anxiety and depression using the Hospital Anxiety and Depression Scale.45
This is a participant-completed outcome measure of anxiety and depression. It is designed to measure
anxiety and depression in participants with physical health problems. It has seven items related to
common symptoms of anxiety and seven items for depression. Participants are asked whether they
experience the symptom definitely, sometimes, not much or not at all. The Hospital Anxiety and
Depression Scale was designed for use in the hospital setting but has been used successfully with the
general population. It was used at baseline and at 6 weeks’ and 6 and 12 months’ follow-up.
Use of health-care and social-care services
l Resource Use Questionnaire.46,47
This is used for collecting retrospective information about trial participants’ use of health- and
social-care services, out-of-pocket expenses and lost earnings. It was administered at baseline and at
6 weeks’ and 6 and 12 months’ follow-up.
Employment
l Questions on employment status, work absence, sick certification and self-certification.
These were used at baseline and at 6 weeks’ and 6 and 12 months’ follow-up.
Process measures (potential predictors and mediators of outcome)
Risk of persistent disabling pain was assessed using the following tools:
l STarT Back Screening Tool.48
This screening tool assesses patients’ risk of persistent disabling pain. Patients’ risk subgroup (low,
medium or high risk) has been shown by team members to be predictive of outcomes, including
patients with back pain and with suspected sciatica. This was measured at baseline only.
l Pain trajectory based on a single question.49
This question is used to classify low back pain duration and asks ‘How long is it since you had a whole
month without any back pain?’. There are seven discrete response categories: < 3 months, 3–6 months,
7–12 months, 1–2 years, 3–5 years, 6–10 years and > 10 years. This shows that recalled duration of
pain is a predictor of outcome in patients with low back pain, independent of baseline severity and
psychological status.
l Pain Self-Efficacy Questionnaire (PSEQ).50
The PSEQ is a 10-item questionnaire, developed to assess the confidence people with ongoing pain
have in performing activities while in pain. The PSEQ is applicable to all persisting pain presentation.
It covers a range of functions, including household chores, socialising and work, as well as coping with
pain without medication. It was used at baseline and at 6 weeks’ and 6 and 12 months’ follow-up.
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l Fear of movement using the Tampa Scale of Kinesiophobia.51
The Tampa Scale of Kinesiophobia is a 17-item checklist that is used to measure the fear of movement
(re)injury related to chronic back pain. The scale is based on the model of fear avoidance, fear of
work-related activities and fear of movement/reinjury. It was used at baseline and at 6 weeks’ and
6 and 12 months’ follow-up.
Follow-up
The questionnaires followed best practice in their design, to maximise response rate. The baseline
questionnaire was administered by the research physiotherapists and completed by the participant. We
planned to send follow-up postal questionnaires at 6 weeks, and at 6 and 12 months. Non-responders
were to be sent an additional copy of the questionnaire. Persistent non-responders were to be contacted
by telephone in order to collect a minimum data set. We planned to contact all participants by telephone
2 weeks after the 12-month questionnaire was sent. This would allow us to collect a minimum data set
from non-responders, and to conduct a a brief semistructured interview with all participants asking about
their overall experience of the trial and subsequent follow-up treatment. Blinding to treatment allocation
would be maintained during these telephone interviews. Once again, in order to assess if blinding had
been maintained, participants would be asked to complete a five-point Likert scale about which treatment
group they believed that they were in.
Assessment of safety
As part of site initiation, training included an overview of possible side effects/potential adverse reactions
associated with adalimumab.
Recording adverse events and adverse reactions
All trial staff and clinicians in contact with trial participants were responsible for noting adverse events
reported by participants and making them known to appropriate medical staff. Trial participants were
encouraged from the outset to contact the research team at the time that an event occurred. Participants
were given a leaflet or card containing a contact address and telephone number. All adverse events,
including non-serious adverse events, were recorded in the participant’s medical records and on their case
report form. All adverse events were reported up to 1 month after the conclusion of the physiotherapy
intervention. Adverse events included:
l an exacerbation of a pre-existing illness
l an increase in frequency or intensity of a pre-existing episodic condition
l a condition (even though it may have been present prior to the start of the trial) detected after trial
drug administration
l continuous persistent disease or symptoms present at baseline that worsened following administration
of the trial treatment.
The following were not included as adverse events:
l medical or surgical procedures in which the condition that led to the procedure was the adverse event
l pre-existing disease or conditions present before treatment that did not worsen
l overdose of medication without signs or symptoms.
METHODS
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Recording serious adverse events and serious adverse reactions
The definition of a serious adverse event was any medical event that:
l resulted in death
l was life-threatening (refers to an event during which the participant was at risk of death at the time
of the event; it does not refer to an event that might have caused death had it been more severe
in nature)
l required hospitalisation, or prolongation of existing hospitalisation
l resulted in persistent/significant disability or incapacity
l was a congenital abnormality or birth defect.
Serious adverse events also included were other important medical events that, based on appropriate
medical judgement, may have jeopardised the participant and may have required medical or
surgical intervention.
Any serious adverse events and serious adverse reactions were recorded in the ‘Investigator Site File’ and
the ‘Trial Master File’.
Statistics
Sample size
From the WMD in our previous meta-analysis,21 we found a relative improvement of 8 points in the ODI at
6 months’ follow-up in the group receiving biological agents compared with placebo, with a standard
deviation of 16 points, giving an effect size of 0.5. In order to detect a more conservative effect size of
0.4 with 90% power, with a significance level of 5% for a two-tailed t-test, a sample size of 133 in each
treatment group was needed. We aimed for a 90% return rate of the final questionnaires but, for a more
conservative retention rate of 80%, 332 participants needed to be recruited. If, as is likely, there was any
correlation between the baseline and outcome measure, the size of effect detectable would be smaller
(or the power to detect a 0.4 effect enhanced).
Recruitment rate
Calculations of recruitment rates for SCIATiC were based on data available from an observational study,
led by co-applicants at Keele, which recruited adult patients seeking treatment in primary care for low
back-related leg pain including sciatica [Assessment and Treatment of Leg pain Associated with the
Spine (ATLAS) trial cohort].39 The ATLAS study recruited 609 patients from 17 general medical practices
(approximate total adult population of 90,200) over 24 months. Analysis of the recruitment data shows
that 219 (36%) participants in this cohort had sciatica with pain in one leg only (with > 80% diagnostic
confidence,) with a RMDQ score of > 7 points (equivalent to an ODI score of ≥ 30 points). On average, per
month, 86 potential participants were identified by GPs and referred to the ATLAS study, 54 attended the
physiotherapy-led research clinic and 25 gave consent and were eligible for the study, nine of whom had a
clinical diagnosis of sciatica (spinal nerve root pain) satisfying the conditions described in Inclusion criteria
and Exclusion criteria in terms of disability score and diagnostic confidence. Based on these figures and
taking into account that in the ATLAS study cohort approximately nine participants per month were
recruited, and making the assumption that half this number would consent to be randomised in a RCT,
our target rate of recruitment was four participants per collaborating centre per month, with centres
covering similar sized populations. For SCIATiC, North Wales, Keele and Cardiff aimed to recruit from
GP practices with a combined registered population of at least 100,000 per centre.
Data analysis
All data were anonymised and coded so that data collection and statistical analysis were performed blind
to treatment allocation. The code would be broken only after the primary analysis had been completed.
The analysis would be performed on a ‘treatment as allocated’ principle to ensure protection against
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unintended bias. The data would be fully imputed using a multiple imputation by chain equations
approach52 in line with a predefined statistical analysis plan to minimise data loss as a result of missing
values or time points. Participants who needed to be referred for disc surgery would be labelled as
‘treatment failures’ and their last test results prior to surgery would be carried forward in the analysis.
Sensitivity analyses (best case/worst case) would be performed to assess the influence of different
imputation assumptions. All trial reporting was Consolidated Standards of Reporting Trials53 compliant.
Primary analysis
The main outcome variable was the ODI measured at 12 months. A linear mixed-model approach for
repeated measures would be used to assess the effects of time and group, while time × group effects
would further describe and explain the overall finding (the interaction term would assess whether or
not the effect of the intervention was the same at each time point). The use of a linear mixed model
for analysis should take care of missing data; however, if imputation was required, then the multiple
imputation by chain equations approach described would have been used. This model would be fully
defined in the statistical analysis plan prior to all analyses. This statistical analysis plan would be approved
by all lead investigators and site principal investigators (PIs), and available for comment by the independent
committees prior to sign-off.
Secondary analysis
Secondary continuous outcome variables would be assessed in a similar way to the primary outcome
variable, with the exception of time to referral for surgery, which would be measured from trial entry (this
is the date of second consent) and analysed using Kaplan–Meier survival analyses and the log-rank test.
Dichotomous variables would be explored using logistic regression. These analyses would be repeated
using prespecified participant subgroups (including the presence of neurological deficit on entry to the
trial and MRI findings). Subgroups would be defined within the statistical analysis plan prior to the
analyses beginning.
Economic analysis
The health economic analysis would adopt the perspective of the NHS and Personal Social Services,
with the inclusion of indirect costs (e.g. time off work) as a secondary analysis. Costs included those of
treatment, tests, procedures and investigations, contact with primary and secondary care services and
personal social services. Resource use would be obtained from participants’ self-reporting of resource use,
captured by questionnaire administration.46,47 Unit cost data would be obtained from standard sources54
and other resources such as the British National Formulary.32 The primary economic outcomes would be
the incremental cost per QALY gained, estimated by administering the EQ-5D-5L at each follow-up point.
The number of QALYs gained by each participant would be calculated as the area under the curve, using
the trapezoidal rule, applying the UK tariffs and corrected for baseline utility score. When appropriate,
missing resource use or health outcome data would be imputed.55 Non-parametric bootstrapped 95% CIs
would be estimated (10,000 replicates). Stratified cost-effectiveness analyses would be conducted on
important, prespecified participant subgroups. Total costs would be combined with QALYs to calculate the
incremental cost–utility ratio of the package of adalimumab plus physiotherapy compared with a 0.9%
sodium chloride injection plus physiotherapy. Estimates of incremental cost–utility ratios would be
compared with the £20,000–30,000 per QALY threshold of cost-effectiveness, and a range of one-way
sensitivity analyses would be conducted to assess the robustness of the analysis. Multivariate sensitivity
analyses would be applied when interaction effects were suspected. The joint uncertainty in costs
and benefits would be considered through the application of bootstrapping and the estimation of
cost-effectiveness acceptability curves.56
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Trial management
Trial Management Group
Individuals responsible for the day-to-day running of the trial were included in a TMG, which included the
chief investigator, lead investigators, PIs, trial manager, statistician, health economist, site co-ordinators,
research staff, data manager and collaborating clinicians, as necessary. The TMG’s role was to monitor all
aspects of the trial’s set-up, conduct and progress. The group ensured that the protocol was adhered to,
and would take appropriate action to safeguard participants and ensure the overall quality of the trial. The
TMG reported to the Data Monitoring and Ethics Committee (DMEC) and Trial Steering Committee (TSC),
and met every 1–2 months.
Trial Steering Committee
A TSC was set up to oversee the running of the trial on behalf of the sponsor and funder, and had the
overall responsibility for the continuation or termination of the trial. The TSC had an independent
chairperson and a majority of independent members and included a patient representative. The role of the
TSC was to ensure that the trial was conducted in accordance with the principles of ‘good clinical practice’
and the relevant regulations, and it provided advice on all aspects of the trial. The trial protocol and any
subsequent amendments were agreed by the TSC. The TSC reported to the TMG, the sponsor and the
funder and it met every 6 months.
Data Monitoring and Ethics Committee
A DMEC monitored the progress of the trial and reviewed all adverse events. The DMEC would have
reviewed results from the internal pilot trial and advised the TSC as needed. It met every 6 months.
Reporting
The TMG reported to the DMEC and TSC. The DMEC reported to the TSC and the TSC reported to the
TMG, the sponsor and the funder. Safety reports were submitted every 6 months to the Research Ethics
Committee (REC), the sponsor and the funder. Development update safety reports were submitted to
the MHRA.
Direct access to source data and documents
Source data were the hospital-written and NHS electronic medical records. Access to these data was
through the participant’s clinicians, physiotherapist and research nurse. Trial-related monitoring, audits,
REC reviews and regulatory compliance inspections were permitted, allowing access to data and
documents when required.
Quality assurance
This trial was conducted in line with the trial protocol and followed the principles of good clinical practice
outlined by the International Committee of Harmonisation Good Clinical Practice E6 (R1) Current Step 4
Version57 and complied with the European Union directive 2001/20/EC.58
A monitoring plan was developed based on a trial risk assessment, which provided details of day-to-day
quality control, audits, etc., and was delegated to members of the trial team to ensure that collected data
adhered to the requirements of the protocol; only authorised persons completed case report forms; the
potential for missing data was minimised; data were valid through validation checks (e.g. range and
consistency checks); and recruitment rates, withdrawals and losses to follow-up were reviewed overall and
by hospital site.
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Data handling
The sources of data for the trial were as follows: recruitment details; baseline outcome measures captured
electronically onto password-protected and encrypted computers by the research physiotherapists or
research nurses; postal questionnaires at 6 weeks’ and at 6 and 12 months’ follow-up entered into the MACRO
system (version 4; InferMed, London, UK); and telephone minimum data collection from non-responders
captured on computers by researchers. Additional health service use data obtained from primary and secondary
care records, with participants’ consent, would be recorded electronically on the computers. Each centre would
input data into the MACRO data management program, which is a web-based system allowing controlled
access to data by all centres and allows a full audit trail.
Trial sponsor
Bangor University (reference number 12/201/02; contact Dr Huw Roberts).
Ethics approval
Wales REC-3 granted approval on 27 May 2015 (15/WA/105). Clinical trial authorisation was approved
from the MHRA on 15 April 2015 (21996/0002/001-0001).
METHODS
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Chapter 3 Results
Trial progress
Funding for the trial was approved by the HTA programme on 11 August 2014; the intention at that
time was for the trial to open in January 2015 and close in June 2018. It had been planned that all the
trial documentation for the regulatory approval for the trial would be completed between July 2014 and
December 2014 so that regulatory approval could be obtained by January 2015.
Five collaborating sites planned to participate in the trial – North Wales, Cardiff, London, Keele and
Nottingham – with training at the five sites taking place between February 2015 and April 2015. The initial
plan was that the trial would be set up and recruiting participants at North Wales and London by April
2015, with the other sites opening to recruitment in June to October 2015. The trial documentation for
the regulatory approval was not in place until December 2014. Regulatory approval was obtained from
the MHRA on 15 April 2015 and from the REC on 27 May 2015. During this time the three English sites
submitted requests for excess treatment costs (ETCs) to the NHS England for Clinical Commissioning
Groups, ETCs for the two Welsh sites were agreed, and contracts were sent to both lead and collaborating
sites from the sponsor, Bangor University. There were delays and unforeseen complexities in obtaining the
ETCs for the English sites. Contracts also proved an issue and caused major delays because of difficulties
with the delegation of the roles and responsibilities and what was required within the different contracts
between university and university, and university and NHS sites. One of the sites withdrew from the trial
in February 2016 because of concerns about the dosage of the biologic used and its patient population,
which was higher than the standard dose used for patients with rheumatoid arthritis but similar to dosage
in other conditions. This withdrawal led to a risk review for the other sites, which felt that, as no new data
were available, the risk of infection for participants was acceptable, and they all agreed to continue
participating in the trial.
The trial opened to recruitment on 8 December 2015 at North Wales and Nottingham, with Keele opening
to recruitment on 11 August 2016. At the time of trial closure, contractual discussions were still ongoing
between Bangor University, Cardiff University and Cardiff and Vale University Health Board.
During this time all sites dealt with a number of challenges. In North Wales, a research physiotherapist was
seconded to the trial in September 2015 but, because of a shortage of physiotherapists in the department,
was required by the health board to return to their previous employment and then left the post in February
2016 for personal reasons. As a result of physiotherapy staffing shortages within Betsi Cadwaladr University
Health Board (BCUHB), the site was unable to employ a replacement research physiotherapist for the
required research physiotherapist time. Participants were identified and recruited via the musculoskeletal
clinic and physiotherapy clinics. The PI at the site contacted fellow consultants throughout the health board
to ensure that all potential participants were identified. Only three participants were recruited at this site
between March and July 2016.
Nottingham had intended to recruit its participants for the trial from the Sherwood Forest Hospitals NHS
Foundation Trust Back Pain Unit diagnostics clinics only, based on pre-study clinic data. During the first
3 months after the start of recruitment at that site, no eligible participants were identified. The site PI
extended screening to include orthopaedic clinics in addition to back pain unit clinics, but without any
significant increase in recruitment. The PI at this site investigated whether or not there had been a change
in referral pathways for people with sciatica in the region that might have affected referrals into these
clinics. The PI confirmed, in February 2016, that this had been the case. GPs had been given direct access
to MRI scans for sciatica, and were requesting and reviewing the results of MRI before requesting opinion
or treatment from the back pain service. As well as introducing delay to referrals, the local GPs were
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tending to refer those with sciatica and a congruent disc prolapse on MRI to an alternative spinal surgical
unit (e.g. Nottingham University Hospitals NHS Trust). A potential participant referred to the PI had already
received MRI, which made them ineligible. Trial progress was an agenda item at the TMG. Owing to
changes in pathways at Sherwood Forest Hospitals NHS Foundation Trust Back Pain Unit, it was agreed by
the TMG that the protocol should be amended to include participants who had already undergone MRI.
This was approved by the REC on 15 April 2016 and by the MHRA on 27 May 2016. During this time,
Sherwood Forest Hospitals NHS Foundation Trust had also been in discussions with local primary care
colleagues to arrange identification of potentially eligible participants from local GP practices through
database searches or opportunistic referral. This was agreed and implemented in June 2016. Sherwood
Forest Hospitals NHS Foundation Trust recruited five participants to the trial between February and
September 2016.
During this period, Keele had obtained agreements for its ETCs and contract negotiations were finalised
between Bangor University and Keele University, and between Bangor University, Keele University and
Royal Wolverhampton NHS Trust, and also between Bangor University, Keele University and Staffordshire
and Stoke-on-Trent Partnership Trust. The Royal Wolverhampton NHS Trust was opened to recruitment on
11 August 2016; one potential participant was identified prior to the trial closure on 20 September 2016.
Randomisation of this participant was not permitted as a result of trial closure on 26 September 2016.
The TSC met on 11 January 2016. The problems with recruitment were discussed at the meeting,
and the members were very sympathetic to the trial team’s frustration of the poor recruitment to the
study. The TSC recommended the following steps if the funders allowed the trial to continue:
1. optimise recruitment for the two sites that were open
2. work harder to reduce bottlenecks (e.g. more MRI slots in North Wales)
3. increase the number of general practices searching for potential participants
4. approach the musculoskeletal triage clinics to join the study as sites
5. inform Keele and Cardiff at the next management group meeting that if they were not about to start
recruiting then they would no longer be part of the trial
6. contact other possible sites that would be able to recruit to the study within the next 6 months.
The chief investigator contacted four sites one each in north, south and mid-Wales, and also the Royal Free
Hospital in London.
Although the additional North Wales site was eager to participate and there was sufficient staff, there was
a lack of clinical space to accommodate the trial within the rheumatology department. The rheumatology
consultant submitted a case to the hospital managers with plans to increase the space available to carry
out clinical trials. Unfortunately, this request was turned down because of competing demands on clinical
space in the hospital, so it was not possible for the rheumatology department to be involved with SCIATiC
and other clinical trials.
The hospital site in south Wales had expressed interest in participating in the trial in April 2016, and the site
was arranging to accommodate the trial when we had to notify them that the trial was terminating early.
The hospital site in mid-Wales had also expressed interest in participating and had notified us on
17 August 2016 that its physiotherapy team had agreed to accommodate the trial. Unfortunately, we
informed the site on 18 August 2016 about the discussions that we had with the funders and the
expected termination of the trial.
The Royal Free Hospital had been discussing increasing their portfolio of clinical trials within the
physiotherapy department and in April 2016 had expressed interest in participating. Unfortunately, it later
informed us that it was doubtful if it would receive funding for the intervention arm of the trial.
The hospital also felt that it would have difficulty recruiting participants with a symptom duration of
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< 6 months. In addition, its rheumatology department did not have spare capacity as it was already busy
with existing research activities.
Owing to concerns with the slow recruitment, the chief investigator and Bangor trial team met with the
funders on 28 January 2016, who informed the trial team that they should:
l finalise existing contracts immediately
l open sites that had not yet opened within the month
l start recruiting from all sites
l complete recruitment to the internal pilot of 50 participants by June 2016.
Another meeting with the funders was held on 16 August 2016. At the meeting the funders requested
that the project team should submit closedown proposals as soon as possible and, ideally, by no later than
31 August 2016. Two different scenarios were proposed:
1. an immediate closedown of recruitment with submission of the project report by the end of
December 2016
2. closure of recruitment in 6 months, until which time the study team should seek to establish the most
effective recruitment routes for any future study, with submission of the project report by the end of
June 2017.
From 16 August to 26 September 2016 only one participant was randomised to the trial by the Sherwood
Forest Hospitals NHS Foundation Trust site. This information was relayed back to the funder, and on
26 September 2016 the chief investigator confirmed that the funders had asked for the trial to be closed
immediately and the project report to be completed by the end of December 2016.
Trial timetable
The trial timetable is outline in Table 2.
Trial recruitment
Recruitment data for the trial are presented in Figure 3 and reasons for withdrawal or exclusion in
Table 3. Sherwood Forest Hospitals NHS Foundation Trust and BCUHB recruited from December 2015 to
September 2016. The Royal Wolverhampton NHS Trust recruited from August 2016 to September 2016.
During this time, eight participants were randomised. No adverse events or adverse reactions were
recorded for any of the participants.
Contracting delays
Site contracts were a major issue. Initial contract templates were drafted in November 2014 but could not
proceed further until the contract and finances were agreed with the funder, and the funder did not
provide these until February 2015. Draft subcontracts were sent to the relevant parties from the Bangor
University contracts department on 31 March 2015.
Betsi Cadwaladr University Health Board: Peter Maddison Rheumatology Centre,
Llandudno Hospital
The subcontract was signed on 8 April 2015; the time taken was 9 days.
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Nottingham University/Sherwood Forest Hospitals NHS Foundation Trust: Rheumatology
Department, King’s Mill Hospital
The subcontract with Sherwood Forest Hospitals NHS Foundation Trust was signed on 20 October 2015;
the time taken was 197 days. The collaborative agreement with Nottingham University was signed on
7 July 2016; the time taken was 378 days.
Initial agreement was sent to Sherwood Forest Hospitals NHS Foundation Trust and Nottingham University
on 31 March 2015. A draft academic agreement was sent to Nottingham University by Bangor University
on 25 June 2015, along with a reminder regarding the NHS contract, and a response was received from
the PI on 16 July 2015. Nottingham queried their costings on 3 August 2015, and costings were confirmed
by Bangor University on 4 May 2016; the collaborative agreement was signed on 7 July 2016. Bangor
University received an update from the Sherwood Forest Hospitals NHS Foundation Trust site on
15 September 2015 stating that they were awaiting an internal response, and the NHS trust contract
was signed on 20 October 2015.
Queen Mary University of London/Bart’s Health NHS Trust: The Royal London Hospital
The collaborative agreement with Queen Mary University of London was signed on 24 July 2015; the time
taken 115 days. The subcontract with Bart’s Health NHS Trust was signed on 14 August 2015; the time
taken was 131 days.
TABLE 2 Trial timetable
Event
Date of completion
Expected Actual
Finalised protocol and trial
documentation
July–December 2014 January 2015
Ethics and NHS R&D permission/MHRA
approvals
September 2014–February 2015 MHRA – April 2015
REC – May 2015
BCUHB R&D approval – July 2015
SFHT R&D approval – November 2015
RWT R&D approval – August 2016
Contracts signed and completed January–March 2015 BCUHB – April 2015
SFHT – October 2015
Bart’s Health NHS Trust – September 2015
RWT – July 2016
Staff training and site initiation March–May 2015 and
November–December 2015
June 2015, July 2015, September 2015
and November 2015
Set up of centres to recruitment February–March 2015 BCUHB – December 2015
SFHT – December 2015
RWT – August 2016
Identification of potential participants February 2015–August 2016 December 2015
Telephone screening March 2015–September 2016 December 2015
Physiotherapy clinical assessment April 2015–October 2016 December 2015
R&D, research and development; RWT, Royal Wolverhampton NHS Trust; SFHT, Sherwood Forest Hospitals NHS
Foundation Trust.
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An initial agreement was sent to Bart’s Health NHS Trust and Queen Mary University of London on
31 March 2015. Bangor University received a response from the site on 21 July 2015 stating that the site
agreed with the terms of the contract. On 24 July 2015, the site contacted Bangor University to say that, as
the template had been approved by the funder, they could move to signature. The collaborative agreement
was signed on 24 July 2015 and the subcontract with the NHS trust was signed on 14 August 2015.
Keele University/Royal Wolverhampton NHS Trust: Cannock Chase Hospital and
New Cross Hospital
The collaborative agreement with Keele University was signed on 2 June 2016; the time taken was
427 days. The subcontract with the Royal Wolverhampton NHS Trust was signed on 7 July 2016; the time
taken was 459 days.
The initial agreement was sent to Keele University on 31 March 2015, with service-level agreements to be
sent to the NHS sites by Keele University. Initial feedback was received from Keele University in May 2015
with a response to these from Bangor University in June 2015. At a meeting on 22 July 2015 in Keele,
contracts were discussed with the trial manager and the research team at Keele University, considering
either (1) a tripartite contract between Bangor University, Keele University and the two sites at Royal
Wolverhampton Hospitals NHS Trust (Cannock Hospital and New Cross Hospital) or (2) a contract from the
sponsor directly to the NHS sites. During further discussions between the contract departments of Bangor
and Keele universities, it was agreed that the following subcontracts would be used: Bangor University and
Keele University, and Bangor University and Royal Wolverhampton Hospitals NHS Trust. Another contract
was also required between Bangor University and Staffordshire and Stoke-on-Trent Partnership Trust,
as patients in the trial would be treated by physiotherapists in Royal Wolverhampton Hospitals or from
Staffordshire and Stoke-on-Trent Partnership Trust. The collaborative agreement was signed on 2 June
2016. Further discussions concerning the delegated duties and wording of the contract to clarify the role of
the NHS sites meant that the subcontract was not agreed and signed until 7 July 2016.
Total number invited
(n = 1546)
Number at first clinical assessment
(n = 25)
Number at second clinical assessment
(placebo, n = 4; adalimumab, n = 4)
Number at first injection
(placebo, n = 4; adalimumab, n = 4)
Number at second injection
(placebo, n = 4; adalimumab, n = 4)
Number at 6-week follow-up
(placebo, n = 4; adalimumab, n = 4)
Number at 6-month follow-up
(placebo, n = 2; adalimumab, n = 1)
Withdrawals and exclusions
(n = 1521) 
Withdrawals and exclusions
(n = 17) 
Withdrawals and exclusions
(n = 0) 
Withdrawals and exclusions
(n = 0)  
Withdrawals and exclusions
(n = 0)  
Withdrawals and exclusions
• Placebo, n = 2
• Adalimumab, n = 3
FIGURE 3 Participant flow diagram for Sherwood Forest Hospitals NHS Foundation Trust, BCUHB and the Royal
Wolverhampton NHS Trust.
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TABLE 3 Reasons for withdrawal and exclusion for patients in Sherwood Forest Hospitals NHS Foundation Trust,
BCUHB and the Royal Wolverhampton NHS Trust
Reason for withdrawal and exclusion n
From invitation to first clinical assessment 1520
Did not confirm interest 963
Symptoms persisting for > 6 months 173
Previous episode of sciatica in the last 6 months 2
Contraindications to MRI 6
Serious spinal pathology 4
Incidental serious pathology identified by MRI 1
Widespread pain throughout body 25
Previous use of biological agents targeting TNF-α 1
Previous lumbar spinal surgery 16
Contraindications to adalimumab 1
Pregnant or breastfeeding 1
Unable to communicate in English or Welsh 3
Mental health problems 3
No sciatica 210
Previous surgery 11
No leg pain 20
Complicated symptoms 18
Pain in both legs 7
Expressed interest but delay in telephone screening attributable to site staffing issues means no longer meet
criteria for inclusion (e.g. no longer in pain or have recently breached the > 22-week exclusion window since
replying)
6
No response or no longer interested 23
Symptoms resolved/improved 10
Current leg pain worse than or as bad as back pain 3
Trial closed early to recruitment 14
From first to second clinical assessment 17
Over time limit for second clinical assessment 1
Study closure 5
Mild symptoms – discharged to GP care 7
TB screening failed 1
Participant revealed long-term history of widespread pain at screening – particularly in shoulders 1
No positive neurological test 1
Patient did not attend appointment and could not be contacted 1
From 6-week to 6-month follow-up 4
Study closure 4
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Cardiff University/Cardiff and Vale University Health Board
The subcontract was still being discussed at the termination of the trial in September 2016, 18 months
after the initial draft had been sent. There were several unresolved issues. Cardiff University decided that
it wanted a tripartite subcontract between Bangor University, Cardiff University and Cardiff and Vale
University Health Board. However, after agreeing to this tripartite agreement, it decided not to sign, as it
wanted to use the Brunswick model agreement.59 Initially MRI was to be undertaken by Cardiff University,
but because this was allocated to the university, rather than the health board, only 80% of the cost would
be reimbursed, and who should pay for this underspend was left unresolved. This delay in signing the
contract also meant that the research physiotherapist seconded to the post was not able to sign her
secondment contract and had to return to her original post. A teleconference took place on 21 January
2016 to resolve the outstanding issues. As a result, an updated subcontract was sent with an updated
work schedule, but remained unsigned.
The funder also requested oversight of all the subcontracts before they were signed. Delays with the
subcontracts led to delays with recruitment and retention of staff at the trial sites. It also meant that a
great deal of trial management time that could have been spent on finding solutions to the slow
recruitment was instead expended on contracting issues.
Withdrawal of site
Eight months after initiation, Bart’s London, one of the larger sites, revisited the risk assessment of the trial
and felt the participant population in its area meant that the 80-mg initial dose would confer a risk of
infection that was higher than acceptable. Bart’s London therefore decided to withdraw its participation in
the trial. This withdrawal led to a risk review for the other sites, all of which felt that, as there were no
new available data, the risk of infection for their participants was acceptable and agreed to continue
participating in the trial.
Recruiting research physiotherapists at sites
It took longer than anticipated to obtain research and development (R&D) approval and set up the site, and
this led to delays in recruiting research physiotherapists. Just after the BCUHB site had opened to recruitment,
the research physiotherapist, who had been seconded to the post from the NHS physiotherapy department,
was required to return to her clinical duties because of staff shortages. This had a negative effect on the trial,
as it halved the physiotherapist time available for screening and recruiting participants to the study at that
site. The chief investigator complained to the department that this removal was jeopardising the trial, and it
was agreed that it would only be for 6 weeks until a locum could be employed. Unfortunately, the same
research physiotherapist went on long-term sick leave and was advised by the health board’s occupational
health department not to return to the post of research physiotherapist. This led to delays in recruiting
participants into the trial and resulted in the loss of some potential participants who had expressed an
interest, as there was no physiotherapist to screen and recruit them.
This resulted in a change of protocol whereby a medically qualified member of staff could be used to
screen potential participants if a research physiotherapist was unavailable. In the interim, Health and Care
Research Wales nurses assisted with the screening of potential participants and another physiotherapist
was assigned to assist with the recruitment of participants to work on the trial for one session per week
for 5 months. A rheumatology registrar was trained in the trial procedures, but was only available to
recruit potential participants for 1 month after regulatory approvals were complete.
Slow recruitment at open trial sites
Recruitment was slower than anticipated in both BCUHB and Sherwood Forest Hospitals NHS Foundation
Trust, which were opened to recruitment on 8 December 2015. Royal Wolverhampton NHS Trust opened
on 11 August 2016; the trial was closed on 26 September 2016. No participants could be recruited by
Royal Wolverhampton NHS Trust in this time.
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In BCUHB, 16 GP practices identified eligible patients presenting at the practice by database searches or
opportunistic referral. An application was made to increase the funding for NHS support costs to cover
the costs of 30 practices, but this was not in place before the trial closed. Musculoskeletal clinics and
physiotherapy departments also searched for eligible patients presenting to their clinics.
At Sherwood Forest Hospitals NHS Foundation Trust, patients referred to the musculoskeletal service
at the rheumatology clinics were screened for eligibility. It was noted by the PI at this site that the number
of sciatica patients referred to the clinics had fallen as a result of a change in the referral pathway
commissioned by the local commissioning group. At this site it was then decided to invite GP practices to
identify eligible patients presenting at the practice, by database search or opportunistic referral. Database
searches commenced at 12 practices in June 2016. A total of 756 potential participants were identified,
11 were invited to first clinical assessment screening and five participants provided consent to participation
before the trial was terminated.
At Royal Wolverhampton NHS Trust, R&D approval was agreed and contracts signed on 7 July 2016, just
before the trial was terminated. One patient was screened but was not invited to provide consent to
participation prior to trial closure.
Excess treatment costs
Applications for ETCs were agreed by the Welsh Government by the two Welsh sites, but agreement for
the three English sites was more problematic. On 4 February 2014, the trial chief investigator asked all
participating sites to submit an application for ETCs. This was submitted by Sherwood Forest Hospitals NHS
Foundation Trust in June 2014, and the ETCs were approved on 11 March 2015. Discussion had also
taken place in Wolverhampton and an application submitted, but ETCs had been declined because of
insufficient funds. This site subsequently explored other potential sources of funding (e.g. from primary
and secondary care, or the pharmaceutical company Abbott UK, if they could provide a discounted or free
drug). On 1 June 2015, the chief investigator requested details of how to obtain a subvention from the
National Institute for Health Research. The chief investigator then contacted the Department of Health and
requested assistance with the matter and was told that the subvention budget is not used to fund specific
study sites and that, as sites for the trial are already signed up for ETCs, they would expect the trust to
cover the costs. Keele led negotiations with both the trust and the Clinical Commissioning Groups in the
West Midlands (Wolverhampton). Owing to anti-TNF-α falling outside payments by results tariff, both
parties argued that they were not funded to support the ETCs associated with this trial. Following
negotiation it was agreed that the local Clinical Commissioning Groups and the trust (charitable funds)
would fund an equal split of the ETCs. ETCs were approved for Royal Wolverhampton NHS Trust on
19 August 2015 and provisional ETCs agreed for Bart’s Health NHS Trust; the trust was told that it would
be finalised once R&D approval was given.
Outcome measure results
The original intention was to use a linear mixed-model approach to assess the effects of time, group and
time × group. This was not possible as data were only available for eight randomised participants on
trial closure. The data for the eight participants are presented. The demographic information is presented
in Appendix 1. Results from all the measures that were collected at different time points are reported in
Appendix 2, with the pain manikin drawings presented separately in Appendix 3. Resource use results are
presented in Appendix 4 and concomitant medications in Appendix 5. Finally, the physiotherapy information is
presented in Appendix 6 and concomitant medications in Appendix 7. It is not possible to make any conclusions
from these data as no analysis was performed.
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Patient and public involvement
The patient and public involvement representative contributed to trial design by commenting on the trial
protocol and patient-facing documents, as well as participating in the TSC meetings. Unfortunately, we
lost contact with the patient and public involvement representative when trial recruitment was closed.
Comments and feedback from the trial management team and
research teams
The trial management team and all sites were asked to reflect on the trial about what worked, and what
did not. The following was noted.
Comments from the trial management team
l We would recommend for future studies that a site feasibility questionnaire be designed and sent out
at an early stage in the trial to all potential sites to inform them on all aspects of the trial design, to
ascertain any potential problems with recruitment and to highlight any logistical challenges that the
potential sites may face.
l Documentation was a problem as the TMG had to approve all of the documents used. Members of the
group would respond separately, not at all or after the documents had been finalised. In order to
provide sufficient clarity and accuracy in the trial documents, we would recommend that documents
should only be sent to the lead investigator and PIs, and discussed at individual site team meetings.
We would recommend that document meetings, to approve trial documents, should be held on a
regular basis and realistic time frames given.
l There were long delays negotiating subcontracts, as much of the contracting discussions focused on
whether the academic partners or the clinical sites were responsible for delivering the randomised
treatment and physiotherapy to the participants. The contracts needed to be between the NHS sites
and the sponsor, with the local universities supporting the process rather than being the contracting
party. There needs to be full discussion between the sponsor’s contracting department and all
academic partners and clinical sites to obtain an early agreement about what the contracts need to
include, and how the contracting process should be arranged, so that the academic partners and
clinical sites have a clear understanding of their delegated roles and tasks.
l Misattribution of costs was another difficulty for this trial. Sites were asked to provide their own
costings on what they required, but some sites had requested funding for their university when it
should have been attributed to the NHS site. We would recommend that each site discuss with its
finance and R&D department where the funding should be attributed and what costings are required.
This needs to be at the application for funding stage.
l Excess treatment costs remained an issue, with no clarity about who was responsible for funding these in
the English sites. Commissioners were investing in a study that might not produce savings in the long term,
and any savings would be realised within secondary care sites and remain hidden from the commissioners.
l Recruitment was difficult, especially as sciatica participants at this stage in their illness would be
managed in primary care, and would not have necessarily been referred to secondary care. These were
not insurmountable issues, but early and regular communication between primary and secondary care
staff would have been beneficial. Changing patient pathways within the NHS between trial design and
completion resulted in challenges at Sherwood Forest Hospitals NHS Foundation Trust. Risk management
plans for recruitment were agreed in advance, and implementation should have been timely.
l Difficulties with recruiting patients within 6 months of symptom onset might prove challenging for
future research in this area. If the proposed mechanism of action of treatment, and lack of availability
of other effective treatments, permits, a longer symptom duration eligibility criterion would be likely to
increase recruitment. Several participants who expressed interest in participation had their symptoms
for > 6 months. It would have been useful to collect data on exactly how far over the threshold these
potential participants were.
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l Our experience raises concerns about secondment of service physiotherapists into research roles, in
which changes in service demands might result in suspension or termination of their secondment.
Availability of dedicated research physiotherapists at sites, or recruitment of research physiotherapists
for the specific study, might have reduced staffing issues. Physiotherapists could have been employed
directly by the trial rather than seconded, as because of departmental shortages, seconded staff had to
resume their previous roles during the agreed seconded period of the trial; this caused major problems
and hindered the recruitment of participants in North Wales.
Comments from the Betsi Cadwaladr University Health Board site in the Peter Maddison
Rheumatology Centre, Llandudno
l Identifying participants from searches of the general practice record database was not very successful;
the uptake from this was very low.
l There were too many components and individuals involved, which affected the success of the trial.
l The trial would have worked better if carried out entirely in primary care.
l Training a research officer with rheumatology experience, or giving a physiotherapist training in
biologic treatments, may have been better than involving a physiotherapist and secondary care
rheumatology nurses.
Comments from the Betsi Cadwaladr University Health Board Physiotherapy Department
Two main areas of difficulty were identified as barriers to the success of SCIATiC from the research
physiotherapist perspective.
1. Recruitment.
¢ The search criteria for the general practice record database were not able to be specific enough and
were poor in identifying exclusion criteria. At telephone triage, many patients had symptoms for
many months, in some cases years, meaning that they were ineligible for the trial. A large proportion
of the research physiotherapist’s time was wasted telephoning people who were not eligible.
¢ Primary care was the main source of patients, but GPs were not universally on board with
identifying patients. Not all of the GPs in the participating practices were aware of the trial, so
suitable patients may have been missed.
2. Logistics.
¢ In the final 6 months from April until September 2016, the time available for the research
physiotherapist to contact patients was limited to 2 hours on one afternoon per week. For 5 weeks
in December 2015 and January 2016 the research physiotherapist had her hours cut by 50% as she
was required to cover the outpatient clinics in the Llandudno physiotherapy department.
¢ The number of patients who were available when telephoned in the afternoons was very low.
¢ The availability of staff such as research nurses and senior clinicians to support the research
physiotherapist was limited as a result of other commitments. It was very difficult to co-ordinate
the biological agent counselling, blood tests etc. Because of the restricted staff availability, it was
difficult to make timely appointments for eligible participants. It was also difficult to co-ordinate the
large number of tests (MRI, T-spot for TB and chest radiography) on 1 day.
¢ Owing to the large geographical surface area of BCUHB, some patients had to travel (in pain) for
up to 2 hours to attend appointments.
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Suggestions for future trials:
l The involvement of the research physiotherapist during the initial planning stage could have helped
recruitment and communication. The funding for the post was delayed and then the appointment of
the research physiotherapist was later than hoped.
l First-contact physiotherapists were not identified as a source of recruitment. Designing the trial to work
with these physiotherapists would have helped identify suitable patients in a timely way.
l Rather than identifying participants from retrospective database searches, clinicians in GP practices
could have identified eligible patients during face-to-face consultations and would have been able to
check for eligibility before they were invited to participate, resulting in a better conversion rate for
trial participation.
l A laminated checklist for each consulting or treatment room containing the inclusion and exclusion
criteria may have helped remind staff about the trial.
l Rather than having a single research physiotherapist with limited days and location, it would have been
better having physiotherapists in a couple of locations, trained to identify suitable patients on the
outpatient waiting list and able to telephone triage to assess eligibility; this would have improved
recruitment.
Comments from the Keele team
Trial set-up
l Two key challenges were agreeing the ETCs at one of our two clinical sites, and the merging of two
clinical rheumatology services at the time of trial set-up. Both of these challenges delayed the start of
the trial significantly.
l Completion of contractual agreements. This trial was a clinical trial of an investigational medicinal
product, and Keele clinical trials unit had recent experience of a MHRA inspection in autumn 2015;
thus, the Keele team was particularly keen to ensure that all the required contracts and sponsorship
arrangements for this trial were clearly in place and appropriate agreements reached about delegation
of responsibilities.
l Many of the clinical staff did not feel fully prepared to commence participant recruitment and
treatment following the November 2015 training session. Further training was developed and delivered
to the research physiotherapists and usual care physiotherapists, supplemented by local working
instructions and/or training packs that the Keele team developed. Further discussions were also
undertaken with the rheumatological nursing staff involved in the trial in the NHS sites to clarify the
study processes and procedures.
Recruitment
l The clinical sites supported by Keele did not have a chance to test the success, or otherwise, of
identification and recruitment processes fully because of the short time between open and close to
recruitment at their sites (from 11 August to 23 September 2016). However, during this time, the
number of potentially eligible patients identified through the GP system searches was smaller
than expected.
l There was a reasonable response rate (14 out of 43) to invitations to the trial, and nearly half of these
(6 out of 14) were from GPs handing trial information packs to patients in the consultation. It is
therefore possible that patients may be more likely to respond if the GP has given them the pack and
potentially discussed the trial with them.
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Comments from the Sherwood Forest Hospitals NHS Foundation Trust: King’s Mill
Hospital Rheumatology Department and Back Pain Unit
Recruitment
l Initial recruitment was through back pain clinics within Sherwood Forest Hospitals NHS
Foundation Trust.
l It would have been beneficial to have had GP recruitment from the start.
l GPs would have screened for patients on a monthly rolling search.
l Good working relationship with the people from the clinical research network who were identifying
participating GPs.
l We could have potentially had five more patients on the study who had given their first consent and
had been screened, but were unable to be randomised as the study was closed to recruitment.
l The clinical research network facilitated recruitment through primary care, which became increasingly
productive. The average recruitment figures did reflect the higher recruitment rate at the time the study
was closed.
Comments from Cardiff
l Very good contact and support form Bangor Trials Unit. Always helpful on the telephone.
l Good support from the PI, as above.
l Flexibility with training packages.
l A major stumbling block was sorting out contracts, which was the main hurdle that, unfortunately, was
not overcome in a timely fashion.
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Chapter 4 Discussion
Summary of main findings
We have demonstrated that a RCT of adalimumab for persistent sciatica of 3–6 months’ duration is
acceptable to some participants. The trial methods were feasible in terms of randomisation method and
outcome measurement. However, recruitment rates were lower than expected and several other factors
contributed to trial termination prior to pilot study completion. We were therefore unable to demonstrate
that this trial was feasible. There was a long delay agreeing and exchanging subcontracts with participating
centres and sites. The contracting discussions with one site were never concluded and another centre
dropped out of the study before recruitment started. There were delays negotiating ETCs for the English
centres and sites. We did attempt to recruit additional sites in Wales, but negotiations were not concluded
at the time of trial closure. Delays in the contracting process also caused delays in recruiting research staff,
in particular the research physiotherapists. In the two sites that did open in time to recruit participants,
recruitment was slow. In one site, the sciatica management pathway changed around the time that it
opened to recruitment. This site initially only relied on referrals to its secondary care musculoskeletal service,
but later involved the primary care research network, which was starting to identify participants just before
trial closure. In the other site there were operational issues identifying the research physiotherapist resource.
This site relied on retrospective GP record review to identify potential participants and although large
numbers of invitations were sent to potential participants, there was a low rate of uptake with only a small
proportion seen for an initial assessment, and entered into the trial. We were in the process of increasing
the number of GP practices within the North Wales area to assist with increasing recruitment; this was not
concluded prior to the trial closure. Recruitment was improving just before the trial was shut down with five
potential participants ready to be recruited within the following month.
Strengths and weaknesses
The trial methods, in terms of randomisation method and outcome measurement, worked smoothly but
for only eight participants, so it is not possible to claim that the methods were feasible. An internal pilot
study was planned, but unfortunately we were unable to recruit sufficient numbers.
We had modelled the numbers of eligible participants for our recruitment projections on the ATLAS cohort
study.39 However, we made unrealistic assumptions about the numbers of identified participants who would
be willing to participate in a clinical trial of an investigational medicinal product. Although we identified
large numbers of potential participants, only small numbers returned reply slips indicating a willingness to
participate. It was not known why eligible participants did not wish to participate. Presumably, some found
the trial procedures too burdensome, such as the complex two-stage recruitment process, whereas others
did not want to participate in a RCT, especially in a clinical trial of an investigational medicinal product
involving a medication with known potential side effects. The ATLAS study cohort was led by the team at
Keele University and recruited 610 participants in 23 months.60 The two clinical sites supported by Keele
signed their contracts just prior to trial closure. Although potential participants had started to be identified,
there was insufficient time to recruit them. Because of this, it was not possible to compare rates of
recruitment into the RCT with those found in the ATLAS cohort study, nor the more recent HTA-funded
Sciatica Outcomes in Primary Care trial using similar methods of identifying participants. One site in east
London dropped out of the trial just before recruitment began because the PI had concerns about patient
safety. The PIs in the other sites reviewed the safety risks to potential participants and felt that these risks
were justified and that measures were in place to mitigate, detect and address any adverse effects. Although
there were only short delays in obtaining research permissions and finalising the trial contract with the
funder, there were very long delays negotiating subcontracts with three of the sites. The difficulty of
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achieving clarity of delegation of functions, and clarity about what needed to be in the different contracts
(university to university vs. university to NHS trusts) are key learning experiences from this trial. Negotiations
concerning ETCs in England were protracted and complex, which added to the delay negotiating contracts
and setting up sites.
Comparison with previous literature
The previous systematic review of biological agents for sciatica found a small number of RCTs and other
studies with small numbers of participants recruited.21 Many of these studies also had poor rates of
recruitment, especially in the UK NHS.24
Implications for future research
A number of factors contributed to the lack of recruitment to the trial. There were delays in contracting,
the process for identifying and recruiting participants was inefficient, there were delays in site set-up
and a lack of investigator engagement (possibly because of a lack of equipoise). After the London centre
withdrew, we asked the other PIs whether or not the research question was still in equipoise. They all
agreed that the risk of infection from the dose of drug administered in this trial was acceptable, and that
they were still in equipoise.
In order to reduce delays in the contracting process, there needs to be an early agreement about what the
contracts need to include, and how the contracting process should be arranged, so that the academic
partners and clinical sites have a clear understanding of their delegated roles and tasks. Early discussions
about site requirements, perhaps using a site feasibility questionnaire, early dialogue with sites’ R&D
departments and the early appointment of research staff in each site would facilitate trial set-up.
We are unable to make any recommendations for future practice in this area because of a lack of trial
results. Without any results from the internal pilot study, it is difficult to make recommendations for future
research in this area. It may be that there is insufficient equipoise around the question of adalimumab for
sciatica among patients and some clinicians. However, this would need to be addressed in further qualitative
research. The two-stage recruitment process was complicated and not feasible. We had modelled the
number of potentially eligible patients on results from the ATLAS cohort study. However, ATLAS did not use
the same two-stage process, nor did it rely on retrospective searches of GP records, but rather relied on the
identification and invitation of eligible patients who were currently consulting their GP for sciatica. The same
recruitment process for ATLAS, which relies on GPs entering relevant diagnostic Read codes into their
computer systems, triggering a ‘pop-up’ reminder about sending eligible patients to dedicated clinics for
further assessment and eligibility checking, has worked in the Sciatica Outcomes in Primary Care (SCOPiC) trial.61
Similar recruitment methods were going to be used in the two sites supported by the Keele co-applicants.
Unfortunately, because of delays in finalising contracts and setting up sites there was insufficient time to
recruit any participants and to test these recruitment methods before trial closure. So, it is still not possible
to say whether or not the use of the recruitment method used in the SCOPiC trial would be feasible for a
similar RCT in the NHS testing an investigational medicinal product.
A trial of biological therapy in patients with sciatica still needs to be done, but would require a clearer
contracting process, qualitative research to ensure that patients would be willing to participate and simpler
recruitment methods.
DISCUSSION
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Appendix 1 Demographic information for each of
the eight randomised participants
Characteristic
Treatment group, participant ID
Placebo Adalimumab
1 2 3 4 5 6 7 8
Site Llandudno
General
Hospital
Llandudno
General
Hospital
King’s
Mill
Hospital
King’s
Mill
Hospital
Llandudno
General
Hospital
King’s
Mill
Hospital
King’s
Mill
Hospital
King’s
Mill
Hospital
Age (years) 46 72 64 59 20 62 68 41
Ethnicity Welsh British English English Welsh English English English
Sex Male Male Female Male Female Female Male Female
Height (cm) 183 180 159 175 167 170 186 164
Weight (kg) 90 83 96 78 88 134 93 76
Employment status FT PT Retired FT PT FT Retired FT
Absent from work as a
result of sciatica?
Yes No N/A Yes Yes Yes N/A Yes
Sickness certificate? Yes No N/A Yes Yes Yes N/A Yes
FT, full-time; ID, identification; N/A, not applicable; PT, part-time.
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Appendix 2 Scores from all of the outcome
measures for each of the eight randomised
participants
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Outcome measure
Treatment group, participant ID
Placebo Adalimumab
1 2 3 4 5 6 7 8
ODI
First clinical assessment 66 36 78 66 76 54 36 60
Second clinical assessment 80 48 76 46 76 54 36 64
6-week follow-up 18 38 72 34 76 64 20 58
6-month follow-up 6 Not completed 74 Not completed Not completed 64 Not Completed Not completed
Global Assessment
Back at 6-week follow-up Much better No change Much worse Much better Worse Better No change Worse
Leg at 6-week follow-up Better No change Much worse Much better Worse No change No change No change
Back at 6-month follow-up Much better Not completed Better Not completed Not completed Better Not completed Not completed
Leg at 6-month follow-up Better Not completed No change Not completed Not completed No change Not completed Not completed
Sciatica Bothersomeness Index
Pain in leg at first treatment 5 4 6 6 5 4 4 6
Numbness or tingling in leg,
foot or groin at first
treatment
5 5 3 6 4 6 4 5
Weakness in foot or leg at
first treatment
5 4 0 0 6 6 4 5
Back or leg pain while sitting
at first treatment
4 6 6 6 5 4 4 5
Pain in leg at 6-week follow-up 2 4 6 3 5 4 6 5
Numbness or tingling in leg,
foot or groin at 6-week
follow-up
4 5 6 3 3 6 6 5
Weakness in foot or leg at
6-week follow-up
5 3 6 4 5 6 6 5
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Outcome measure
Treatment group, participant ID
Placebo Adalimumab
1 2 3 4 5 6 7 8
Back or leg pain while sitting
at 6-week follow-up
2 5 5 2 6 4 4 5
Pain in leg at 6-month
follow-up
0 Not completed 5 Not completed Not completed 4 Not completed Not completed
Numbness or tingling in leg,
foot or groin at 6-month
follow-up
4 Not completed 3 Not completed Not completed 6 Not completed Not completed
Weakness in foot or leg at
6-month follow-up
4 Not completed 0 Not completed Not completed 6 Not completed Not completed
Back or leg pain while sitting
at 6-month follow-up
1 Not completed 6 Not completed Not completed 4 Not completed Not completed
EQ-5D-5L
State at first treatment 33333 32231 43452 33342 33543 45433 32332 32442
Score at first treatment 0.63 0.76 0.15 0.46 0.31 0.38 0.67 0.37
Scale at first treatment 70 55 40 65 40 25 55 30
State at 6-week follow-up 21131 22331 43453 11231 43542 43434 21232 32332
Score at 6-week follow-up 0.88 0.76 0.12 0.88 0.19 0.19 0.75 0.67
Scale at 6-week follow-up 80 65 30 80 40 40 50 35
State at 6-month follow-up 21221 Not completed 43452 Not completed Not completed 43434 Not completed Not completed
Score at 6-month follow-up 0.84 Not completed 0.15 Not completed Not completed 0.19 Not completed Not completed
Scale at 6-month follow-up 85 Not completed 50 Not completed Not completed 40 Not completed Not completed
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Outcome measure
Treatment group, participant ID
Placebo Adalimumab
1 2 3 4 5 6 7 8
Hospital Anxiety and Depression Scale
Anxiety score at first
treatment
12 3 6 4 15 17 10 10
Depression score at first
treatment
7 4 10 13 9 14 7 10
Total score at first treatment 19 7 16 17 24 31 17 20
Anxiety score at 6-week
follow-up
2 3 12 9 11 13 5 10
Depression score at 6-week
follow-up
3 3 16 6 13 12 5 10
Total score at 6-week follow-up 5 6 28 15 24 25 10 20
Anxiety score at 6-month
follow-up
2 Not completed 6 Not completed Not completed 13 Not completed Not completed
Depression score at 6-month
follow-up
1 Not completed 10 Not completed Not completed 12 Not completed Not completed
Total score at 6-month
follow-up
3 Not completed 16 Not completed Not completed 25 Not completed Not completed
Keele STarT Back Screening Tool
First treatment 6 5 7 3 8 8 6 5
Subscore at first treatment 3 1 4 2 4 4 3 4
Tampa Scale of Kinesiophobia
First treatment 45 Not completed 40 56 42 40 44 41
6-week follow-up 34 32 41 47 48 42 40 41
6-month follow-up 38 Not completed 40 Not completed Not completed 43 Not completed Not completed
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Outcome measure
Treatment group, participant ID
Placebo Adalimumab
1 2 3 4 5 6 7 8
Group Likert scale
6-week follow-up Equally likely to
be in the 0.9%
sodium chloride
injection group or
the adalimumab
injection group
Equally likely to
be in the 0.9%
sodium chloride
injection group or
the adalimumab
injection group
More likely to
be in the 0.9%
sodium chloride
injection group
Equally likely to
be in the 0.9%
sodium chloride
injection group or
the adalimumab
injection group
More likely to
be in the
adalimumab
injection group
Equally likely to
be in the 0.9%
sodium chloride
injection group or
the adalimumab
injection group
Definitely in the
0.9% sodium
chloride
injection group
More likely to
be in the
adalimumab
injection group
6-month follow-up More likely to be
in the 0.9%
sodium chloride
injection group
Not completed More likely to
be in the 0.9%
sodium chloride
injection group
Not completed Not completed Equally likely to
be in the 0.9%
sodium chloride
injection group or
the adalimumab
injection group
Not completed Not completed
PSEQ
First treatment 26 48 8 17 9 14 30 9
6-week follow-up 41 34 3 46 7 21 37 9
6-month follow-up 50 Not completed 10 Not completed Not completed 21 Not completed Not completed
RMDQ
Back at first treatment 21 Not completed 19 0 21 23 1 0
Leg at first treatment 21 Not completed 18 19 21 23 19 24
Back at 6-week follow-up 3 Not completed 20 7 21 21 0 0
Leg at 6-week follow-up Not completed Not completed 16 10 18 22 9 23
Back at 6-month follow-up 2 Not completed 19 Not completed Not completed 21 Not completed Not completed
Leg at 6-month follow-up 3 Not completed 18 Not completed Not completed 21 Not completed Not completed
ID, identification.
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Appendix 3 Completed pain manikins for all
eight participants randomised
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Appendix 4 Results from the Resource Use
Questionnaire for all eight randomised participants
Time point of assessment
Treatment group, participant ID
Placebo Adalimumab
1 2 3 4 5 6 7 8
First clinical assessment
Bought medicines from
pharmacy or other retailer?
Yes No No No Yes No No Yes
Cost to nearest pound (reasons
related to sciatica)
20 N/A N/A N/A 36 N/A N/A 100
Cost to nearest pound (other
reasons)
0 N/A N/A N/A 0 N/A N/A 0
Did you travel by private car for
any of your visits?
Yes Yes Yes Yes No Yes Yes Yes
Miles (reasons related to sciatica) 25 0 22 3 N/A 28 3 10
Miles (other reasons) 0 0 0 0 0 0 0 0
Did you travel by bus, train or
taxi for any of your visits to GP
surgeries or hospital visits?
No No No No No No No No
Cost (reasons related to sciatica) N/A N/A N/A N/A N/A N/A N/A N/A
Cost (other reasons) N/A N/A N/A N/A N/A N/A N/A N/A
Number of GP surgery visits
(reasons related to sciatica)
0 2 2 3 12 3 3 7
Number of GP surgery visits
(other reasons)
0 0 0 0 0 0 0 0
Number of GP out-of-hours
surgery visits (reasons related to
sciatica)
0 0 0 0 0 0 0 0
Number of GP out-of-hours
surgery visits (other reasons)
0 0 0 0 0 0 0 0
Number of GP home visits
(reasons related to sciatica)
0 0 0 0 0 0 0 0
Number of GP home visits (other
reasons)
0 0 0 0 0 0 0 0
Number of A&E visits (reasons
related to sciatica)
0 0 0 0 1 0 0 0
Number of A&E visits (other
reasons)
0 0 0 0 0 0 0 0
Number of outpatient clinic visits
(reasons related to sciatica)
0 0 3 0 9 3 0 0
Number of outpatient clinic visits
(other reasons)
0 0 0 0 0 0 0 0
Number of outpatient day-case
visits (reasons related to sciatica)
0 0 0 0 0 0 0 0
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Time point of assessment
Treatment group, participant ID
Placebo Adalimumab
1 2 3 4 5 6 7 8
Number of outpatient day-case
visits (other reasons)
0 0 0 0 0 0 0 0
Number of inpatient visits 0 0 0 0 0 0 0 0
Number of visits to
physiotherapist
5 0 0 0 0 0 0 0
Cost (£) 0 N/A N/A N/A N/A N/A N/A N/A
Number of acupuncture sessions 0 0 0 0 0 0 0 0
Cost (£) N/A N/A N/A N/A N/A N/A N/A N/A
Number of visits to osteopath/
chiropractor
0 0 0 1 0 0 0 0
Cost (£) N/A N/A N/A 37 N/A N/A N/A N/A
Number of other services outside
hospital
0 0 0 0 0 0 0 0
Cost (£) N/A N/A N/A N/A N/A N/A N/A N/A
Your number of days off (to
nearest half day) (reasons related
to sciatica)
27 0 0 0 80 84 0 0
Lost earnings (to nearest pound)
(reasons related to sciatica)
0 N/A N/A N/A 600 0 N/A N/A
Your number of days off (to
nearest half day) (other reasons)
0 0 0 0 0 0 0 0
Lost earnings (to nearest pound)
(other reasons)
N/A N/A N/A N/A N/A N/A N/A N/A
Family member/friend number of
days off (to nearest half day)
(reasons related to sciatica)
0 0 0 0 15 0 0 0
Family member/friend lost
earnings (to nearest pound)
(reasons related to sciatica)
N/A N/A N/A N/A 700 N/A N/A N/A
Family member/friend number of
days off (to nearest half day)
(other reasons)
0 0 0 0 0 0 0 0
Family member/friend lost
earnings (to nearest pound)
(other reasons)s
N/A N/A N/A N/A N/A N/A N/A N/A
6-week follow-up
Bought medicines from
pharmacy or other retailer?
No Not
completed
Yes No Yes No No Yes
Cost to nearest pound (reasons
related to sciatica)
N/A Not
completed
50 N/A 84 N/A N/A 100
Cost to nearest pound (other
reasons)
N/A Not
completed
0 N/A 0 N/A N/A 0
Did you travel by private car for
any of your visits?
Yes Yes Yes No Yes Yes Yes Yes
Miles (reasons related to sciatica) 2 40 60 N/A N/A 20 4 20
Miles (other reasons) 0 0 0 0 0 0 0 0
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Time point of assessment
Treatment group, participant ID
Placebo Adalimumab
1 2 3 4 5 6 7 8
Did you travel by bus, train or
taxi for any of your visits to GP
surgeries or hospital visits?
No No No No No No No No
Cost (reasons related to sciatica) N/A N/A N/A N/A N/A N/A N/A N/A
Cost (other reasons) N/A N/A N/A N/A N/A N/A N/A N/A
Number of GP surgery visits
(reasons related to sciatica)
0 0 1 0 2 0 0 7
Number of GP surgery visits
(other reasons)
0 0 0 0 0 0 0 0
Number of GP out-of-hours
surgery visits (reasons related to
sciatica)
0 0 0 0 0 0 0 0
Number of GP out-of-hours
surgery visits (other reasons)
0 0 0 0 0 0 0 0
Number of GP home visits
(reasons related to sciatica)
0 0 0 0 0 0 0 0
Number of GP home visits (other
reasons)
0 0 0 0 0 0 0 0
Number of A&E visits (reasons
related to sciatica)
0 0 1 0 0 0 0 0
Number of A&E visits (other
reasons)
0 0 0 0 0 0 0 0
Number of outpatient clinic visits
(reasons related to sciatica)
0 0 0 0 2 0 2 0
Number of outpatient clinic visits
(other reasons)
0 0 0 0 0 0 0 0
Number of outpatient day-case
visits (reasons related to sciatica)
0 0 0 0 0 0 0 0
Number of outpatient day-case
visits (other reasons)
0 0 0 0 0 0 0 0
Number of inpatient visits 0 0 0 0 0 0 0 0
Number of visits to
physiotherapist
0 4 0 0 0 0 0 0
Cost (£) N/A 0 N/A N/A N/A N/A N/A N/A
Number of acupuncture sessions 0 0 0 0 0 0 0 0
Cost (£) N/A N/A N/A N/A N/A N/A N/A N/A
Number of visits to osteopath/
chiropractor
0 0 0 0 0 0 0 0
Cost (£) N/A N/A N/A N/A N/A N/A N/A N/A
Number of other services outside
hospital
0 0 0 0 0 0 0 0
Cost (£) N/A N/A N/A N/A N/A N/A N/A N/A
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Time point of assessment
Treatment group, participant ID
Placebo Adalimumab
1 2 3 4 5 6 7 8
Your number of days off (to
nearest half day) (reasons related
to sciatica)
0 0 0 0 120 42 0 18
Lost earnings (to nearest pound)
(reasons related to sciatica)
0 0 0 0 950 0 0 0
Your number of days off (to
nearest half day) (other reasons)
0 0 0 0 0 0 0 0
Lost earnings (to nearest pound)
(other reasons)
N/A N/A N/A N/A N/A N/A N/A N/A
Family member/friend number of
days off (to nearest half day)
(reasons related to sciatica)
0 0 0 0 2 0 0 0
Family member/friend lost
earnings (to nearest pound)
(reasons related to sciatica)
N/A N/A N/A N/A 240 N/A N/A N/A
Family member/friend number of
days off (to nearest half day)
(other reasons)
0 0 0 0 0 0 0 0
Family member/friend lost
earnings (to nearest pound)
(other reasons)
N/A N/A N/A N/A N/A N/A N/A N/A
6-month follow-up visits
Bought medicines from
pharmacy or other retailer?
Yes Not
completed
No Not
completed
Not
completed
No Not
completed
Not
completed
Cost to nearest pound (reasons
related to sciatica)
2 Not
completed
N/A Not
completed
Not
completed
N/A Not
completed
Not
completed
Cost to nearest pound (other
reasons)
N/A Not
completed
0 Not
completed
Not
completed
0 Not
completed
Not
completed
Did you travel by private car for
any of your visits?
No Not
completed
Yes Not
completed
Not
completed
Yes Not
completed
Not
completed
Miles (reasons related to sciatica) N/A Not
completed
20 Not
completed
Not
completed
20 Not
completed
Not
completed
Miles (other reasons) N/A Not
completed
0 Not
completed
Not
completed
0 Not
completed
Not
completed
Did you travel by bus, train or
taxi for any of your visits to GP
surgeries or hospital visits?
No Not
completed
No Not
completed
Not
completed
No Not
completed
Not
completed
Cost (reasons related to sciatica) N/A Not
completed
N/A Not
completed
Not
completed
N/A Not
completed
Not
completed
Cost (other reasons) N/A Not
completed
N/A Not
completed
Not
completed
N/A Not
completed
Not
completed
Number of GP surgery visits
(reasons related to sciatica)
0 Not
completed
2 Not
completed
Not
completed
0 Not
completed
Not
completed
Number of GP surgery visits
(other reasons)
0 Not
completed
0 Not
completed
Not
completed
0 Not
completed
Not
completed
Number of GP out-of-hours
surgery visits (reasons related to
sciatica)
0 Not
completed
0 Not
completed
Not
completed
0 Not
completed
Not
completed
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Time point of assessment
Treatment group, participant ID
Placebo Adalimumab
1 2 3 4 5 6 7 8
Number of GP out-of-hours
surgery visits (other reasons)
0 Not
completed
0 Not
completed
Not
completed
0 Not
completed
Not
completed
Number of GP home visits
(reasons related to sciatica)
0 Not
completed
0 Not
completed
Not
completed
0 Not
completed
Not
completed
Number of GP home visits (other
reasons)
0 Not
completed
0 Not
completed
Not
completed
0 Not
completed
Not
completed
Number of A&E visits (reasons
related to sciatica)
0 Not
completed
0 Not
completed
Not
completed
0 Not
completed
Not
completed
Number of A&E visits (other
reasons)
0 Not
completed
0 Not
completed
Not
completed
0 Not
completed
Not
completed
Number of outpatient clinic visits
(reasons related to sciatica)
0 Not
completed
2 Not
completed
Not
completed
0 Not
completed
Not
completed
Number of outpatient clinic visits
(other reasons)
0 Not
completed
0 Not
completed
Not
completed
0 Not
completed
Not
completed
Number of outpatient day-case
visits (reasons related to sciatica)
0 Not
completed
0 Not
completed
Not
completed
0 Not
completed
Not
completed
Number of outpatient day-case
visits (other reasons)
0 Not
completed
0 Not
completed
Not
completed
0 Not
completed
Not
completed
Number of inpatient visits 0 Not
completed
0 Not
completed
Not
completed
0 Not
completed
Not
completed
Number of visits to
physiotherapist
0 Not
completed
0 Not
completed
Not
completed
0 Not
completed
Not
completed
Cost (£) N/A Not
completed
N/A Not
completed
Not
completed
N/A Not
completed
Not
completed
Number of acupuncture sessions 0 Not
completed
0 Not
completed
Not
completed
0 Not
completed
Not
completed
Cost (£) N/A Not
completed
N/A Not
completed
Not
completed
N/A Not
completed
Not
completed
Number of visits to osteopath/
chiropractor
0 Not
completed
0 Not
completed
Not
completed
0 Not
completed
Not
completed
Cost (£) N/A Not
completed
N/A Not
completed
Not
completed
N/A Not
completed
Not
completed
Number of other services outside
hospital
0 Not
completed
0 Not
completed
Not
completed
0 Not
completed
Not
completed
Cost (£) N/A Not
completed
N/A Not
completed
Not
completed
N/A Not
completed
Not
completed
Your number of days off (to
nearest half day) (reasons related
to sciatica)
0 Not
completed
0 Not
completed
Not
completed
43 Not
completed
Not
completed
Lost earnings (to nearest pound)
(reasons related to sciatica)
N/A Not
completed
N/A Not
completed
Not
completed
0 Not
completed
Not
completed
Your number of days off (to
nearest half day) (other reasons)
0 Not
completed
0 Not
completed
Not
completed
0 Not
completed
Not
completed
Lost earnings (to nearest pound)
(other reasons)
N/A Not
completed
N/A Not
completed
Not
completed
N/A Not
completed
Not
completed
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Time point of assessment
Treatment group, participant ID
Placebo Adalimumab
1 2 3 4 5 6 7 8
Family member/friend number of
days off (to nearest half day)
(reasons related to sciatica)
0 Not
completed
0 Not
completed
Not
completed
0 Not
completed
Not
completed
Family member/friend lost
earnings (to nearest pound)
(reasons related to sciatica)
N/A Not
completed
N/A Not
completed
Not
completed
N/A Not
completed
Not
completed
Family member/friend number of
days off (to nearest half day)
(other reasons)
0 Not
completed
0 Not
completed
Not
completed
0 Not
completed
Not
completed
Family member/friend lost
earnings (to nearest pound)
(other reasons)
N/A Not
completed
N/A Not
completed
Not
completed
N/A Not
completed
Not
completed
A&E, accident and emergency; ID, identification; N/A, not applicable.
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Appendix 5 Concomitant medications for all
eight randomised participants
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Medication
Treatment group, participant ID
Placebo Adalimumab
1 2 3 4 5 6 7 8
Concomitant medications first clinical assessment
Number of
concomitant
medications
0 5 8 4 9 5 10 0
Medication name l Capasal Therapeutic
Shampoo (Dermal
Laboratories Ltd,
Hitchin, UK)
as required
l Esomeprazole
20 mg once daily
l Mebeverine 135 mg
once daily
l Solifenacin
(Vesicare®; Astellas
Pharma Ltd, Tokyo,
Japan) 5 mg once
daily
l Pregabalin 75 mg
once daily
l Omeprazole 20 mg
once daily
l Simvastatin 40 mg
once daily
l Ramipril 10 mg
once daily
l Venlafaxine 75mg
once daily
l Aspirin 75 mg
once daily
l Metformin 500 mg
once daily
l Gliclazide 40 mg
twice daily
l Temazepam 20mg
once daily
l Lansoprazole 30 mg
once daily
l Gabapentin
l Paracetamol 1 g
every 4 hours
l Naproxen 250mg
l Thyroxine 75 µg
once daily
l Omeprazole 20 mg
once daily
l Loestrin® (Galen Ltd,
Craigavon, UK)
once daily
l Sertraline 100 mg
once daily
l Diazepam 2mg
three times daily
l Gabapentin 300 mg
three times daily
l ZOMORPH
(Ethypharm UK Ltd,
High Wycombe, UK)
20 mg twice daily
l Paracetamol 1 g
three times daily
l Ibuprofen 40mg
three times daily
l Gabapentin 600mg
three times daily
l Paracetamol 1 g as
required
l Bendroflumethiazide
2.5 mg once daily
l Losartan 100 mg
once daily
l Bezafibrate 400mg
once daily
l Zapain (Concordia
International Rx UK
Ltd, London, UK)
30 mg four
times daily
l Diclofenac 50 mg
three times daily
l Diazepam 2mg
three times daily
l Amitriptyline 10 mg
once daily
l Lisinopril 20 mg
once daily
l Lixisenatide
(Lyxumia®; Sanofi,
Paris, France) 20 µg
once daily
l Felodipine 2.5 mg
once daily
l Gliclazide 80 mg
twice daily
l Metformin 850 mg
twice daily
l Atorvastatin 40 mg
once daily
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Medication
Treatment group, participant ID
Placebo Adalimumab
1 2 3 4 5 6 7 8
Concomitant medications first treatment
Number of
concomitant
medications
0 5 0 0 11 5 0 0
Medication name l Capasal therapeutic
shampoo,
as required
l Esomeprazole
20 mg once daily
l Mebeverine 135 mg
once daily
l Solifenacin 5 mg
once daily
l Pregabalin 275 mg
once daily
l Paracetamol 1 g
as required
l Ibuprofen 400mg
three times daily
l Thyroxine 75 µg
once daily
l Omeprazole 20 mg
once daily
l Loestrin once daily
l Sertraline 100 mg
once daily
l Diazepam 2mg
three times daily
l Gabapentin 300 mg
3 times daily
l ZOMORPH 20mg
twice daily, then
ZOMORPH 20mg
once daily, then
ZOMORPH 30mg
once daily
l Gabapentin 600mg
three times daily
l Paracetamol 1 g
every 4 hours
l Bendroflumethiazide
2.5 mg once daily
l Losartan 100 mg
once daily
l Bezafibrate 400mg
once daily
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Medication
Treatment group, participant ID
Placebo Adalimumab
1 2 3 4 5 6 7 8
Concomitant medications second treatment
Number of
concomitant
medications
0 5 0 0 0 0 0 0
Medication name l Capasal therapeutic
shampoo as
required
l Omeprazole 20 mg
once daily
l Mebeverine 135 mg
once daily
l Solifenacin 5 mg
once daily
l Pregabalin 300 mg
once daily
ID, identification.
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Appendix 6 Physiotherapy treatment received for
all eight randomised participants
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Physiotherapy
treatment
Treatment group, participant ID
Placebo Adalimumab
1 2 3 4 5 6 7 8
Number of physiotherapy
courses
1 Not completed 4 6 1 6 6 4
Advice, education and
reassurance?
0 Not completed 4 5 5 4 5 5
Medication usage
discussion/review?
0 Not completed 1 0 2 1 2 0
Specific exercise: stability 0 Not completed 2 2 0 3 3 0
Specific exercise:
McKenzie
1 Not completed 2 4 0 2 3 0
Specific exercise: neural
glides
1 Not completed 0 4 0 0 3 1
Specific exercise: other 1 Not completed 2 1 1 4 3 2
Details Gluteus maximus
maximum stretch
Not completed Mobilisation
exercises,
reduced exercise
Strength and
relaxation
Posture Mobilisation
exercises,
balance
Iliotibial band,
piriformis
stretch
General mobility
and flare up
Joint mobilisations/
manipulations
0 Not completed 0 0 0 0 0 0
Soft tissue techniques 0 Not completed 0 0 0 0 0 0
Other treatment 0 Not completed 2 4 5 0 4 3
Details N/A Not completed Relaxation CD,
paired walking
Posture
limitations and
postural
structure
Acupuncture N/A Advice on
overactivity,
swimming, use
of heat
Relaxation and
visualisation
Action plan for relapse
discussed
Not completed Not completed 2 Not completed Not completed 4 1 Not completed
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Physiotherapy
treatment
Treatment group, participant ID
Placebo Adalimumab
1 2 3 4 5 6 7 8
Outcome Not completed Not completed Interface GP Spinal
orthopaedics
GP GP Spinal
orthopaedics
Comments Patient seen for
initial assessment.
Given exercises,
however, patient
cancelled follow-up
appointments
Not completed Not completed Not completed Patient continued
to have five
further treatments
of acupuncture
Not completed Not completed Not completed
CD, compact disc; ID, identification; N/A, not applicable.
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Appendix 7 Concomitant medications reported
during physiotherapy for all eight randomised
participants
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Medication
Treatment group, participant ID
Placebo Adalimumab
1 2 3 4 5 6 7 8
Number of
concomitant
medications
1 8 7 5 10
Medication
name
l Zapain l Omeprazole 20 mg once daily
l Simvastatin 40 mg once daily
l Ramipril 10 mg once daily
l Venlafaxine 75mg once daily
l Temazepam 20mg once daily
l Aspirin 75 mg once daily
l Metformin 500 mg once daily
l Gliclazide 40 mg twice daily
l Thyroxine 25 µg once daily
l Sertraline 100mg once daily
l Loestrin once daily
l Omeprazole 20 mg once daily
l ZOMORPH 20mg twice daily
l Diazepam 2mg three
times daily
l Gabapentin 300 mg three
times daily
l Gabapentin 600mg three
times daily
l Paracetamol 1 g as required
l Bendroflumethiazide 2.5 mg
once daily
l Losartan 100 mg once daily
l Bezafibrate 400 mg once daily
l Zapain 30 mg four times daily
l Diclofenac 50 mg three
times daily
l Diazepam 2mg three
times daily
l Amitriptyline 10 mg once daily
l Lisinopril 20 mg once daily
l Lixisenatide 20 µg once daily
l Felodipine 2.5 mg once daily
l Gliclazide 80 mg twice daily
l Metformin 850 mg twice daily
l Atorvastatin 40 mg once daily
ID, identification.
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Appendix 8 Milestones
Project milestone
Completion date
Delay (months)Proposed Actual
Year 1
Finalise protocol and trial
documentation
December 2014 December 2014 0
Set up TMG September 2014 October 2014 1
Ethics approval December 2014 May 2015 5
R&D approval December 2014 July 2015–August 2016 7–20
Design patient packs and
CRFs
December 2014 April 2015 4
Design, validation and
set-up of study database
January 2015 August 2015 (testing) 7
Randomisation set-up February 2015 April 2015 2
DMEC and TSC meetings November 2014 DMEC: June 2015
TSC: November 2014
DMEC: 7
TSC: 0
Physiotherapists recruited
and in post
Month 1: January 2015 BCUHB: September 2015 8
SFHT: already in post 0
Keele: already in post 0
Cardiff: March 2016 14
London: December 2015 11
Set-up of centres Month 1: January 2015 BCUHB: site opened December 2015 11
SFHT: site opened December 2015 11
Keele: site opened July 2016 18
Cardiff Not obtained before
trial closed by
funder
London Withdrew February
2016
BCUHB: further training June,
September, November 2015
5
Keele: further training November 2015 10
SFHT: further training July 2015 6
Cardiff: further training January,
March 2016
12
London: further training June 2015 5
Identification of potential
participants
Month 1- February 2015 BCUHB: December 2015 10
SFHT: January 2016 11
Keele: August 2016 18
Cardiff Not obtained before
trial closed by
funder
London Not applicable
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Project milestone
Completion date
Delay (months)Proposed Actual
Telephone screening Month 3: March 2015 BCUHB: December 2015 9
SFHT: February 2016 11
Keele: July 2016 17
Cardiff Not obtained before
trial closed by
funder
London Not applicable
Recruitment of
participants – pilot study
Month 4: April 2015 BCUHB: March 2016 11
SFHT: February 2016 10
Keele Not obtained before
trial closed by
funder
Cardiff Not obtained before
trial closed by
funder
London Not applicable
Baseline and
randomisation – pilot
study
Month 5: May 2015 BCUHB: March 2016 10
SFHT: February 2016 9
Keele Not obtained before
trial closed by
funder
Cardiff Not obtained before
trial closed by
funder
London Not applicable
Physiotherapy clinical
assessment
Month 4: April 2015 BCUHB: March 2016 11
SFHT: March 2016 11
Keele Not obtained before
trial closed by
funder
Cardiff Not obtained before
trial closed by
funder
London Not applicable
Post out 6-week follow-
up – pilot study
Month 7: July 2015 BCUHB: April 2016 9
SFHT: April 2016 9
Keele Not obtained before
trial closed by
funder
Cardiff Not obtained before
trial closed by
funder
London Not applicable
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Project milestone
Completion date
Delay (months)Proposed Actual
Year 2
Post out 6-month
follow-up
Month 10: October 2015 BCUHB: September 2016 11
SFHT: August 2016 10
Keele Not obtained before
trial closed by
funder
Cardiff Not obtained before
trial closed by
funder
London Not applicable
Complete 6-month
follow-up
Month 11: November
2015
BCUHB: September 2016 10
SFHT: September 2016 10
Keele Not obtained before
trial closed by
funder
Cardiff Not obtained before
trial closed by
funder
London Not applicable
Post out 12-month
follow-up
Month 16: April 2016 Due February 2017 Not obtained before
trial closed by
funder
Complete 12-month
follow-up
Month 17: May 2016 Due March 2017 Not obtained before
trial closed by
funder
Pilot study analysis review
and report
Month 11: November
2015
Eight participants recruited –
November 2016
Early termination
Data cleaning and
preparation for analysis
Month 10: October 2015 Eight participants recruited –
November 2016
Early termination
Statistical and economic
analysis
Month 20: August 2016 Eight participants recruited –
November 2016
Early termination
Statistical and economic
write-up
Months 4 and 37: April
2015 and January 2018
Eight participants recruited –
November 2016
Early termination
Data monitoring, quality
assurance and cleaning
Months 6–39: July
2015–March 2018
Trial monitored throughout set-up and
during trial as per normal procedures
0
Site closure, preparation
for archiving
Months 27 and 29: March
2017 and March 2018
Owing to early termination, site closure
and archiving December 2016
Early termination
Year 3
Write up of final report Month 37: January 2018 Eight participants recruited – November
2016
Early termination
Dissemination Month 40: April 2018 Owing to early termination,
dissemination will be January 2017
Early termination
CRF, case report form; SFHT, Sherwood Forest Hospitals NHS Foundation Trust.
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Appendix 9 Progress summary
Description Timeline Future action required Current status
Finalisation of all
documentation
Agreed by TSC and TMG:
26 January 2015
None Complete
Approval by Bangor
University Ethics
Committee
9 March 2015 None Complete
MHRA approval 15 April 2015 None Granted/complete
REC approval 27 May 2015 None Granted/complete
Trial closed as a result
of poor recruitment
23 September 2016 Report written, sites notified and
regulatory bodies notified
Ongoing
Five sites scheduled to participate in SCIATiC
Betsi Cadwaladr University Health Board: Peter Maddison Rheumatology Centre
Llandudno Hospital
Description Timeline Future action required Current status
R&D approval 9 July 2015 None Complete
Contracts signed 8 April 2015 None Complete
Research
physiotherapist
15 September 2015 None In place/complete
Site initiation 1 June 2015; further training
provided on 28 September
2015 and 23 November 2015
None Complete
Site opened to
recruitment
8 December 2015 None Complete
Participant screening Started 8 December 2015 None Complete
Trial participants January 2016 Scheduled for randomisation on
18 January 2016 – participants did not
attend. First participant randomised
1 March 2016, three participants recruited
Complete
Sherwood Forest Hospitals NHS Foundation Trust: Rheumatology Department,
King’s Mill Hospital
Description Timeline Future action required Current status
R&D approval 20 November 2015 None Granted/complete
Contracts signed 20 October 2015 None Complete
Site initiation 28 July 2015 None Complete
Site opened to
recruitment
8 December 2015 None Complete
Participant screening Screening of participants in
clinic started January 2016
None Ongoing
Trial participants March 2016 Five participants recruited Ongoing
DOI: 10.3310/hta21600 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 60
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
85
Bart’s Health NHS Trust: The Royal London Hospital
Description Timeline Future action required Current status
R&D approval Ongoing at time of site
withdrawal
None Not applicable as
site withdrew
Contracts signed 23 September 2015 None Complete
Research
physiotherapist
Ongoing at time of site
withdrawal
None Not applicable as
site withdrew
Initiation performed 23 June 2015 None Complete
Royal Wolverhampton NHS Trust: Cannock Chase Hospital and New Cross Hospital
Description Timeline Future action required Current status
R&D outstanding 10 August 2016 None Complete
Contracts
outstanding
7 July 2016 None Complete
Initiation 26 November 2015 None Complete
Site opened to
recruitment
August 2016 None Complete
Participant screening September 2016 One participant screened; no participants
randomised before trial closure
Complete
Cardiff and Vale University Health Board
Description Timeline Future action required Current status
R&D approval Ongoing at time of early
termination of trial
Final queries to be answered by site Outstanding
Contracts Ongoing at time of early
termination of trial
In discussion with Bangor University and
Cardiff and Vale University Health Board
Outstanding
Initiation Ongoing at time of early
termination of trial
Due Outstanding
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Appendix 10 Participant information sheets in
English and Welsh
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Appendix 11 Consent forms in English
and Welsh
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Appendix 12 Case report forms including
telephone screening and baseline questionnaire
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The following questionnaires were also used:
l leg pain version of RMDQ38,41
l STarT Back Tool47
l SBI42
l HADS44
l Graddfa Pryder ac Iselder Ysbyty (HADS)44
l RUQ45,46
l Pain Manikin43
l PSEQ49
l fear of movement using the TSK.50
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